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ABSTRACT

The population approach to pharmacokinetic involves the estimation of mean
pharmacokinetic parameters and their variability within a study population. Advantages
of this approach include the ability to i) utilize sparse data, ii) analyze data from large,
heterogeneous populations to obtain realistic and relevant estimates of variability and iii)
evaluate the influence of patient characteristics on pharmacokinetic estimation.

Sparse data from a phase ill clinical trial of the protease inhibitor, nelfinavir, were used
to obtain estimates of the pharmacokinetic parameters and their variability. The effects of
patient covariates on the pharmacokinetic parameters of nelfinavir were evaluated.
Clearance, estimated from data in the latter part of a dosing interval, was estimated well
due to random spread of the data in this part of the concentration-time profile. Only the
influence of concomitant administration of the azole antifungal agent, fluconazole was
statistically significant resulting in a reduction in clearance of 30% . Problems arose in the
estimation of volume of distribution and the absorption rate constant and their variability.
The lack of early samples and the lack of variability in the timing of these samples
contributed to the difficulty in estimating these parameters.

A simulation study was designed to investigate design issues including the ability to
detect a sub-population with a 30% reduction in clearance. A one-compartment model
with intravenous input was employed. Different designs consisting of 2 samples per
individual in 100 individuals were evaluated at two levels of interindividual variability
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(30% and 60%). When interindividual variability was 30%, a sub-population of 20
individuals could consistently be identified and the pharmacokinetic parameters of the
model could be accurately estimated. Estimates of the variability parameters were less
accurate but acceptable using some designs. When interindividual variability was 60%,
no design could consistently identify the sub-population even when the sub-population
was 30, and no design provided accurate estimates of all of the parameters. Overall, the
performance of one design, which consisted of three sampling windows covering the
whole dosing interval, proved superior to the other designs investigated. Increasing the
total sample size and using the FOCE method in NONMEM improved the ability of this
design.
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PREFACE

(

This document was prepared in the format of the manuscript plan in accordance to
section 11-3 of the Graduate School Manual at the University ofRhode Island. The
dissertation is divided into three sections.

Section I contains a general introduction to the objectives of the research . Section TI
consists of the main body of this dissertation. This section is composed of three
manuscripts written in the format required for each scientific journal to which they are, or
will be, submitted. A statement of overall conclusions for the entire dissertation is also
included in this section. Section Ill contains 1 appendix that includes additional
information and experimental details useful to the understanding of the work in section II.
A bibliography follows section Ill in which all sources used as references in this
document are cited.
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INTRODUCTION

(

Pharmacokinetics is the study of the relationship between a given dose of a drug and the
plasma concentrations achieved over time. Traditionally pharmacokinetic studies are
usually conducted in a small, homogeneous group of individuals (1 - 3). After
administration of the study drug each individual provides an extensive number of plasma
samples that are then used to obtain estimates of that individual ' s pharmacokinetic
parameters. Summary statistics of the parameter values within that group can then be
calculated using standard methods. There are many advantages to this approach such as
the statistics are straightforward and familiar to scientists and there are many years of
experience using this methodology. However, there are also limitations e.g. only a small
number of individuals can be studied and subjects tend to be either healthy volunteers or
patients with a mild form of the disease and thus are not representative of the true
population to be treated .

An alternative method to traditional pharmacokinetic analysis is the population approach

to pharmacokinetic analysis (1 -4). A major difference between the two methods is that
the population approach can use data consisting of only a few samples per patient (2,3).
The unit of analysis is the study population. The population approach is used in a single
step to obtain point estimates of the mean pharmacokinetic parameters and their
variability within the population under investigation (2) . As population pharmacokinetic
studies tend to be conducted in a large, heterogeneous population the influence of
demographic and physiological characteristics on the pharmacokinetics of the drug can
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be assessed . This method, like the traditional approach, has many potential benefits such
as the ability to utilize sparse data and the ability to study larger populations more
representative of the true population to be treated . There are also limitations to the
approach that need to be recognized e.g. the unfamiliar and complex statistics and
computer software and the lack of use of this technique to date.

One of the major advantages of the population approach is the ability to utilize only a few
(even as little as one) samples per individual (2, 3). However the method can equally be
applied to data that is rich or a combination of both rich and sparse data (1). Historically
in phase ill trials, random trough samples may be taken from some individuals to monitor
compliance (5), which in many cases has been the only use of this data. The population
approach is ideally suited to the analysis of this kind of data. By using the population
approach useful information can be obtained on the pharmacokinetics of a new drug
using data that already exists. This can be accomplished for little additional cost except
for the cost of the actual analysis itself.

However a note of caution is necessary. It must be realized that the quality of an analysis
is highly dependent on the design of the study and the quality of the data obtained. Thus,
in order for the population approach to be implemented effectively, the design of the
study and the collection of the data must be given careful consideration (5, 6).

Important aspects of study design to be considered include the number of individuals to
include in the study, the number of samples per individual (e.g. a fixed number per
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individual or variable numbers) and the timing of sampling (e.g. optimal times, sampling
windows or sampling completely at random). All levels of these factors must be chosen
so that sufficient information is available to estimate the pharmacokinetic and variability
parameters of interest. If the effect of a patient characteristic on a pharmacokinetic
parameter is to be evaluated then it is important to ensure that the size of the subpopulation possessing that characteristic is adequate to detect the effect. In terms of the
data itself, accurate dosing and sampling records and the documentation of covariate
information are important considerations.

In short, the population approach to pharmacokinetic analysis has the potential to provide
high quality, relevant information on a drug' s pharmacokinetics from sparsely sampled
data if the study is conducted in an appropriate manner.
(

4

(

HYPOTHESIS TESTED IN TIDS PROJECT

Design of population pharmacokinetic studies is an area of active investigation. Several
simulation studies investigating issues such as the number of samples per individual, the
timing of samples and the number of total individuals in the study necessary to produce
accurate parameter estimates have been reported in the literature. As this approach is
intended for use in situations when only sparse data is available such as a phase III
clinical trial, then consideration must be given to these issues. In particular, the
information available on pharmacokinetic parameters and their variability is highly
dependent on the number of samples obtained per individual and the timing of these
samples.

The influence of the size of a sub-population possessing a characteristic that significantly
influences a pharmacokinetic parameter on the ability to detect that population in an
analysis has received little attention. There are no formal studies in the literature that
specifically address this issue and in instances when this design consideration is
mentioned, the authors have chosen the size of the sub-population based upon their own
experiences (7, 8).

The hypothesis to be tested in this research is that the population approach to
pharmacokinetic analysis can be applied to sparsely sampled data to obtain precise and
unbiased estimates of pharmacokinetic parameters and their variability and to distinguish
significant covariate effects.
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OBJECTIVES
The objectives of this research project are:
1. To determine the pharmacokinetic parameters of a marketed drug using a sparse

sampling design (observational data) .
2. To determine if the study design is adequate to accurately determine these
parameters.
3. To evaluate the influence of patient covariates on the pharmacokinetics of this drug.

Using simulated data:
4. To evaluate the ability to accurately measure the pharmacokinetic parameters of an
intravenously administered drug using a sparsely sampled study design consisting of
only two samples per individual.
5. To determine the influence of the size of a sub-population possessing different
pharmacokinetic characteristics on the ability to detect that sub-population.
6. To assess the ability to estimate the value of the pharmacokinetic parameter in the
sub-population.
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SECTION II
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MANUSCRIPT I

r

Application of Population Pharmacokinetics to the Drug Development Process
*published in Drug Development and Industrial Pharmacy 24(12) 1155-1162 (1998).

ABSTRACT
Population pharmacokinetics is playing an increasing role in clinical drug development.
An overview of the population approach, including software and the advantages and

limitations of the approach compared to the traditional approach to pharmacokinetic
studies, is given. This paper also documents how the area has evolved over the past 15
years and addresses some of the issues that have arisen over the design and conduct of
population studies. Finally, some alternative applications of the population approach are
given for areas other than clinical drug development.
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INTRODUCTION
Pharmacokinetics is the study of the relationship between the dose of a drug and the
manner in which its plasma concentrations change over time. A pharmacokinetic model
provides a mathematical representation of this relationship and relates the independent
variables of time and dose to the dependent variable, plasma concentration, using
pharmacokinetic parameters such as clearance (CL) and volume of distribution (Vd).
Pharmacodynamics is the study of the relationship between concentrations of the drug at
the site of action and its physiological effect.

The traditional approach to pharmacokinetic studies involves taking intensive samples,
up to 10 or 20 per individual, from a small group of subjects or patients. The data from
each subject are individually fitted to a pharmacokinetic model (e.g., a one- or twocompartment model) to obtain that individual ' s pharmacokinetic parameters. Then,
summary statistics such as the mean and the variance of the group are calculated based on
each individual ' s pharmacokinetic parameters. Initially, these studies are often performed
on healthy volunteers, especially in phase I clinical studies.

The population approach to the analysis of pharmacokinetic data also provides estimates
of the average value of pharmacokinetic parameters in a study population and gives a
measure of the variability of these parameters within that population (1). In contrast to
the traditional approach, the population approach is based on only a few samples from
each subject in a larger number of subjects. In addition, the population approach provides
parameter estimates from the population of individuals in a single step. A population
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model generally consists of two components: a pharmacokinetic or structural model and a
pharmacostatistical model. As a result, the term mixed effects modeling is often used to
describe the modeling process since two types of parameters are estimated: the fixed
effect parameters associated with the pharmacokinetic model and the random effect
parameters that describe the pharmacostatistical model (2).

Fixed effect parameters describe the relationship between the plasma concentration and
the fixed effects. Fixed effects include the dose, physiological factors such as age, weight
and creatinine clearance and other factors such as concomitant medications. Fixed effect
parameters include typical pharmacokinetic parameters such as volume of distribution
(Vd) and clearance (CL) and proportionality constants that quantify the relationship
between a pharmacokinetic parameter such as clearance and a fixed effect such as
creatinine clearance (1-3).

Random-effect parameters are used to quantify variability in pharmacokinetic parameter
estimates that arise due to interindividual (between subjects) and intraindividual (within
subject) variations (1). Interindividual variability is the random between subject
variability that cannot be explained in terms of fixed effects. It is important to obtain an
estimate of unexplainable variability for a new drug because the safety and efficacy of a
drug tends to decrease as unexplainable variability increases (4) . Intraindividual
variability is the variability that occurs within an individual. It includes errors that arise
from the measurement of drug concentrations, model misspecification due to
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oversimplification of the model, and random variation in a patient's pharmacokinetic
parameters that can occur over time (1 ,2,4,5).

There are numerous articles in the literature that can be consulted to provide a more
comprehensive review of the theory and methodology underlying the population
approach to pharmacokinetic analysis (1-3 ,5-8) .

COMPUTER SOFTWARE
Software development for population analyses is an active area of investigation, and a
number of programs are currently available. A meeting of experts was held in 1994 to
discuss software issues associated with the analysis of population pharmacokinetic and
pharmacodynamic data. The participants concluded that programs need to be userfriendly with good graphical interfaces, have the ability to specify complex
pharmacokinetic and pharmacodynamic models, and be able to handle sparse data (9).
NONMEM (Nonlinear Mixed Effects Modeling) (10) is the software most often used and
tested for these analyses (9, 11 ). Other currently available software includes NPML (NonParametric Maximum Likelihood) (12), NPEM (Non-Parametric Expectation
Maximization) (13) and the programs that implement the Bayesian approach using Gibbs
sampling (14) .

Each method of applying the population approach has its own assumptions and
limitations. Some researchers have advocated using several methods to analyze one
dataset as a means of confirming results and of highlighting problems in methodology
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(9,15). A comparative study carried out in 1992 under the initiative of the American
Statistical Association compared four population modeling methods: NONMEM, Gibbs
sampling, SPML (semi-parametric maximum likelihood) and NPML. They showed that
the different methods gave similar results, with only minor discrepancies observed (9). In
1997, the Population Pharmacokinetic Modeling Workgroup formed by the
Biopharmaceutical Section of the American Statistical Association compared population
methods using two simulated data sets (11). Their report included analyses performed
using seven different modeling programs: NONMEM, a conditional first-order method
implemented in S-Plus (16), two alternative first-order methods implemented in SAS (1719), the Bayesian approach using Gibbs sampling (14), a semi-non-parametric approach
(20) and NPML (12). The statistical theory and methodology underlying these software
programs can be found in the literature (5,7,12-14,16-20). The group observed
differences in some parameter estimates when the different approaches were compared.
Thus, there appears to be conflicting evidence regarding the comparability of some
methods of implementing the population approach and this subject requires further
investigation.

ADVANTAGES AND LIMITATIONS OF THE POPULATION APPROACH
In contrast to traditional studies, the population approach to pharmacokinetic studies
requires fewer samples per patient. Thus, these designs are more suited to the study of
sub-populations such as pediatrics, geriatrics and the very ill (e.g. AIDS and cancer
patients or patients with renal and hepatic impairment), for whom there are ethical
constraints to taking many blood samples per patient (3 ,5, 7).
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Traditional pharmacokinetic studies often involve volunteers or patients with mild forms
of the disease of interest, and inclusion and exclusion criteria are often very strict. Thus,
these patients/subjects are not very representative of the population to be treated, and the
pharmacokinetics of the study drug for these patients may differ significantly from the
pharmacokinetics of patients who receive the drug in clinical practice (21 ). As fewer
samples are required per patient in a population study, it is feasible to study a greater
number of patients. For example, if a population pharmacokinetic study is incorporated
into a phase III clinical trial, patients under study are more representative of the
population for which the drug will eventually be used; thus the results of the analysis are
of more relevance to the population of interest. Also, as the patient population is
generally more heterogeneous, it becomes possible to examine the effect of various
patient characteristics (e.g., age, weight, renal function, concomitant medications) on the
pharmacokinetics of the drug. Thus, if a population analysis is incorporated into a phase
II or III trial, then drug disposition can be evaluated early in the development process,
and the results used to guide dosage recommendations in different sub-populations (4).

Traditional studies are expensive to conduct due to their strict scientific design, so only a
small number of individuals can be studied, which can result in poor estimates of
interindividual variability. In contrast, a population study can be done using observational
data, that is, data collected under less-restrictive conditions, such as in clinical practice,
than in a traditional study. The requirement for fewer samples per individual and the use
of routine data enables a population study to be conducted less expensively. Plasma
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samples are often obtained periodically from subjects enrolled in phase III trials to
monitor compliance. Therefore, if these samples were used in a population
pharmacokinetic study, there would be minimal additional cost to the sponsor.

A limitation to the use of population pharmacokinetic methods is the complex data
analysis techniques involved. In contrast, the analysis of traditional pharmacokinetic data
is relatively straightforward and is performed using common, simple statistical methods
(3). The observational design of a population study does not provide as convincing
evidence for causation as the rigid scientific control of a traditional pharmacokinetic
study. However, traditional studies are done in patients often not representative of the
population of interest, which makes the relevance of the results questionable.

INTEGRATION OF POPULATION PHARMACOKINETICS IN THE DRUG
DEVELOPMENT PROCESS
In 1983, a discussion paper on the testing of drugs in the elderly was issued by the Food

and Drug Administration (FDA). It advocated the inclusion of population
pharmacokinetic studies as part of phase III clinical trials (22). Initially, there was a
negative reaction from the pharmaceutical industry to this suggestion for a number of
reasons ( 4). First, the method of data analysis was unfamiliar to most scientists, and the
complex nature of the analytical technique demanded specialized expertise. There was
the belief that identification of a factor influencing the pharmacokinetics of the drug
during drug development could result in the FDA requiring a prospective study to
investigate this possible influence. Some believed that incorporating a population
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pharmacokinetic study into a trial protocol could result in additional cost and reduced
compliance with the study protocol. Finally, there were questions regarding the quality of
the data used in such an analysis (3 ,4,23 ,24).

By the late 1980s to early 1990s, a number of applications of the population approach had
appeared in the literature, they were summarized by Sheiner and Ludden in 1992 (7).
However, the majority were carried out in a clinical setting after marketing of the drug
and were not performed in the pre-approval process (25).

At this time, Grasela and colleagues published a series of articles in which they evaluated
the use of population pharmacokinetics in clinical drug development (21 ,26-28). They
applied the population approach in four different scenarios: a phase III clinical trial of
patients who contributed only a few plasma samples each, a phase III clinical trial
designed to detect a drug-drug interaction, a prospectively designed clinical trial that
included forms designed to collect and record information relating to plasma sampling
and dosing specifically for determining population pharmacokinetics, and finally, a
postmarketing surveillance study that had limited control of design issues. They found
that parameter estimates obtained using the population approach in all situations were
comparable to estimates obtained in traditional pharmacokinetic studies and thus
confirmed the potential use of this methodology in phase III and IV studies.

An interdisciplinary conference was held in April 1991 to discuss the integration of
pharmacokinetics in rational drug development (29). The report from the conference
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advocated the use of population approaches in phase III trials to identify those patient
characteristics that influence the pharmacokinetics of a drug in different subpopulations
and to use this information in drug labeling. It was accepted that a population
pharmacokinetic analysis was not the primary objective of phase II, III and IV trials; thus,
the methods for a population pharmacokinetic study, which must be incorporated into the
efficacy protocol, should be as simple as possible and not have an impact on the major
goals of the study (30,31).

In March 1995, a meeting of experts was held to discuss design issues associated with
conducting population pharmacokinetic and pharmacodynamic studies (30). The
experiences of the committee were that the population approach had frequently been
implemented successfully in phase II and phase III studies. The consensus was that
population pharmacokinetics should be included in clinical trials, and the discussion
focused on design issues associated with the inclusion of a population pharmacokinetic
study in a phase II or phase III efficacy trial.

A report published in 1996 on the implementation of the population approach in clinical
drug development proposed many instances in which the population approach could
successfully be employed in the drug development process from the preclinical stage to
postmarketing studies (15). Phase I studies provide initial information on the
pharmacokinetics and pharmacodynamics of a drug in human subjects, usually healthy
volunteers (29). Intensive sampling, as employed in traditional pharmacokinetic studies,
is advocated at this stage to establish an initial pharmacokinetic profile for the drug (15).
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However, if data from sufficient patients can be pooled, then the population approach can
be applied at this stage. An advantage in doing this is that the data from all patients can
be fit to the same pharmacokinetic model (i.e., a one- or two-compartment model)
whereas in traditional studies, different models may sometimes be fit to data from
different patients (15).

Phase II studies are used to determine initial efficacy data in relatively small groups of
patients with the disease to be treated and to investigate the dose-response relationship
(29) . A more rational design of subsequent clinical studies can be undertaken if the
population approach is applied at this stage to investigate variability in response and
relationships with covariates (15).

Phase ill clinical trials are designed to confirm the efficacy of a drug and to establish a
toxicity profile (29). It is often the nature of these studies to exclude patients with diverse
characteristics (e.g. , patients with renal or hepatic disease) to increase the statistical
power of the study. It is these patients whose pharmacokinetic profile is most likely to
differ and whose dosage regimen may need to be individualized. As a solution to this
problem, Vozeh et al. proposed that these patients be included in the study as a satellite
group whose data would be excluded from the efficacy assessment, but included in the
population pharmacokinetic analysis (15).

In September 1997, the FDA issued proposed guidelines to govern the conduct and

analysis of population pharmacokinetic studies in the drug development process (32) .
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Design issues associated with these studies were discussed in the guidelines. Obviously,
the issues depend to some extent on what stage in the drug development process
(preclinical, phase I - ID or postmarketing) in which the analysis is being conducted as
this drives the kind of data collected. The new regulations proposed by the FDA, which
are to require companies to conduct extensive clinical studies in the pediatric population
during drug development, provide an opportunity for the wide application of the
population approach (33).

ISSUES ASSOCIATED WITH THE DESIGN AND CONDUCT OF A
POPULATION PHARMA CO KINETIC STUDY
There are a number of fundamental requirements to fulfill in order to conduct a good
population pharmacokinetic study. A sensitive and specific assay is needed to measure
plasma concentrations of parent drug and clinically relevant metabolites; confirmation
from preliminary studies is required to demonstrate a correlation between drug or
metabolite concentrations and clinically relevant effects; and last, preliminary
pharmacokinetic studies should have established the basic pharmacokinetic model to
describe the drug' s disposition, although population analyses of sparse data may use less
complex structural models than are required in data-rich situations (2,4,9).

The draft documentation issued by the FDA governing the conduct of population
pharmacokinetic studies discussed some of the issues involved in designing a population
pharmacokinetic study. These include the number of subjects required for a population
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analysis, the number of samples required per subject, and the optimum time of sampling
(32). Simulation studies and real data sets are being used to investigate these issues.

In the early 1980s, Sheiner and Beal conducted three simulation studies with designs that

were based on three experiments, each consisting of 10 subjects who were extensively
sampled. They found that estimates of interindividual variability were imprecise as a
result of the small number of individuals, even though each individual provided many
samples (34). In another study, they used a one-compartment intravenous model to
simulate data. They found that when the total number of samples were fixed at
approximately 100, the bias and precision of pharmacokinetic and variability parameters
were comparable when the data consisted of three samples from 33 patients or two
samples from 50 patients. However, estimates were less precise and more biased when
the data consisted of four samples from 25 patients (3 5).

One study investigated the number of samples per patient and the total number of
samples necessary to provide accurate pharmacokinetic parameter estimates of
cyclosporine in liver transplant patients (36) . The data consisted of 203 samples from 42
individuals and was analyzed using a one-compartment model implemented in NPEM.
Estimates of clearance and volume of distribution converged and showed very little
variation once there were two levels per patient and the total number of patients in the
analysis reached 15-20. Others found that analyses using either two or three samples per
patient provided estimates that were not significantly biased or imprecise when compared
with the intense sampling strategy (37) .
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A simulation study using a two-compartment model with intravenous input found that
pharmacokinetic parameter estimates were accurate using from four to six samples per
subject for 100 subjects, but interindividual variabilities were biased using the foursample design (38). Also in this study, the effect of the number of subjects was assessed
using a six-sample design. They evaluated seven levels from 20 to 100 subjects and
found that all pharmacokinetic parameters were comparable irrespective of the sample
size, but estimates of interindividual variability became less biased as the number of
subjects increased.

Another group used simulated data to mimic sparsely sampled data for 100 patients from
a phase III clinical trial in which either one or two blood samples were taken per patient
on two occasions (39). They compared various sampling strategies for bias and precision
of population parameter estimates and found that parameter estimates were often more
precise and less biased when patients provided two samples per visit as compared to only
one.

Thus, it appears that two samples per individual for 30 to 50 individuals can provide
accurate estimates of population average parameters. However, more individuals and
more samples per patient may be required to obtain unbiased estimates of interindividual
variability (40). Obviously, the specific pharmacokinetic model used to fit the data and
the number of parameters to be estimated has an impact on the number of samples
required per individual.
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Some researchers have advocated the use of random sampling of plasma concentrations
within the population (21 ,3 0). However, it is likely that the quality of information
obtained will increase if informative sampling times are selected. Samples obtained at the
time of peak serum concentrations usually contain the most information about the volume
of distribution, whereas samples obtained in the middle of a dosing interval are
informative about clearance (2). Others have employed Optimal Sampling Theory (OST)
to reduce the number of samples required per subject (41 ,42). This method ensures that
data are collected at informative times for estimation of pharmacokinetic parameters
(37,43-47). These studies investigated various sampling schedules and pharmacokinetic
models; in all cases, the optimally sampled, reduced data sets provided accurate estimates
of clearance, often the parameter of most interest. In some, but not all, cases, other
(

pharmacokinetic parameters were also accurately estimated.

The quality of the data used in a population analysis is of paramount importance. Ette,
Sun, and Ludden investigated the use of balanced (i .e. , equal number of samples per
patient) versus unbalanced data and found that the precision of parameter estimates, but
not accuracy, was affected by missing data (48). Sun et, al. conducted a simulation study
to investigate the effect of misrecorded sample times on parameter estimation in
NONMEM (49). Obviously a well designed study may not provide good results if sample
times are not recorded accurately. Sun, Ette, and Ludden found that estimates of
clearance tended to be unbiased when errors were random or systematically positive
whereas the estimate of clearance was biased when there was a negative systematic error.

(
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One study compared prospectively and retrospectively collected data (27). Specific forms
were designed to collect and record information related to plasma sampling and dosing in
the prospective study. Patient records were used to obtain information in the retrospective
study. The prospective study was found to produce pharmacokinetic estimates
comparable to previously reported estimates from traditional studies, whereas the
retrospective study yielded biased estimates. The results from these studies demonstrate
the need for good quality data in order to conduct a meaningful population
pharmacokinetic analysis.

Validation of population pharmacokinetic models (i.e., ifthe parameter estimates and
covariates included in a model based on one set of data can be reproduced with another
set of data) is an area of current interest (32). The various approaches that have been used
to date, such as data splitting and the bootstrap resampling technique, have recently been
discussed (50).

In summary, there are many ongoing issues in the design and conduct of population
pharmacokinetic analyses . It appears that two samples per patient for 100 patients would
be a reasonable minimum number of patients and samples required to develop a
population pharmacokinetic model. It should be noted that the number of samples
obtained from each subject depends on the number of pharmacokinetic parameters to be
estimated (21). Thus, care should be taken when extrapolating results from specific
situations that use particular pharmacokinetic models to other situations. A well-planned
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study protocol which describes the objectives and methodology for conducting a
population pharmacokinetic analysis is required . It should include a specific form that is
simple in design to record sample times and dosing history. Education of clinical
investigators is also essential to ensure that good quality data is obtained.

OTHER APPLICATIONS OF POPULATION PHARMA COKINETICS
Although the majority of discussion has involved the implementation of the population
approach in clinical drug development, there is interest in using these methods in preclinical development, although application of the population approach in preclinical
studies is still relatively sparse.(15 ,51-54). Two examples can be found in the literature
that investigate the use of the population approach in one animal species only (53 ,54).

Both studies used a one sample per animal design, which is often the case in preclinical
studies. The first study showed that variability in volume of distribution could be partially
explained due to gender differences, and the second study produced unbiased and precise
estimates of the pharmacokinetic parameters. However, both studies were unable to
separate interindividual from intraindividual variability and thus did not provide good
estimates of variability.

The use of the population approach to investigate the pharmacokinetics and influence of
covariates in a single species requires further study to show that it is a meaningful and
cost-effective analysis to undertake. A potential application of the population approach in
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preclinical studies is to analyze data from a number of animal species in order to
investigate allometric relationships using weight as a covariate (15).

Therapeutic drug monitoring (TDM) is applied in clinical practice to monitor the plasma
concentrations of drugs that have a narrow therapeutic range. TDM is used to
individualize the dose in order to avoid subtherapeutic levels of the drug or unwanted
toxic effects (55). Relevant prior pharmacokinetic parameter estimates are required in
order to implement TDM (56). Population pharmacokinetic studies can be used to
provide these a priori estimates, and there are many examples in the literature where
pharmacokinetic parameters that have been derived from population analyses to be used
in this manner (see the summary by Thomson and Whiting, Ref. 56).

CONCLUSIONS
The population approach to pharmacokinetic studies is a new field that is rapidly growing
and gaining acceptance in the pharmaceutical arena. The population approach can be
used to analyze data that consists of only a few samples per individual. Thus, it is ideall y
suited to analyze observational data that is collected during clinical studies to monitor
compliance, data pooled from early phase traditional pharmacokinetic studies, and data
collected through routine clinical practice in postmarketing studies.

The population approach provides estimates of the mean population pharmacokinetic
parameters within a population and variability of these estimates within that population.
This method partitions the variability into between variability and within variability, and
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it can be used to explain the variability in pharmacokinetic parameter estimates in terms
I

of physiological fixed effects. In doing so, this method can provide information on
possible patient subgroups at risk of excessive drug accumulation or subtherapeutic
levels, and it can be used to develop guidelines for drug dosage individualization (2,4).

The advent of proposed guidelines from the FDA that govern the design and conduct of
population pharmacokinetic studies supports the use of these studies in the drug
development process.
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ABSTRACT
A population pharmacokinetic analysis was conducted on nelfinavir in patients infected
with Human Immunodeficiency Virus (HIV), who were enrolled in a phase III clinical
trial. The data consisted of 509 plasma concentrations from 174 patients who received
nelfinavir at a dose of 500 mg or 750 mg three times a day. The analysis was performed
using NONMEM. A one-compartment model with first-order absorption best described
the data. The timing and number of early post dose blood levels did not allow accurate
estimation of volume of distribution (V d/F) and the absorption rate constant (ka). As a
result, two models were used to analyze the data, Model 1 in which oral clearance
(CL/F), V d/F and ka were estimated and Model 2 in which Vd/F and ka were fixed and
only CL/F was estimated. The values of Vd/F and ka were fixed to those obtained from
analysis of data from 19 intensely sampled HIV patients enrolled in a traditional
pharmacokinetic study. Estimates of CL/F ranged from 41.9 - 45 .1 L/h, values in close
agreement with previous studies. Neither body weight, age, gender, race, dose level,
baseline viral load, CYP2C19 metabolizing status, history of liver disease nor raised liver
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function tests appeared to be significant covariates for clearance. A low CD4 count and
concomitant use of a macrolide antibiotic or fluconazole were significant when tested
alone. However once concomitant use offluconazole was incorporated into the model as
a covariate for CL/F, the other covariates no longer achieved statistical significance.
Patients who received concomitant therapy with fluconazole experienced a statistically
significant reduction in CL/F of 26 - 30% . This is unlikely to be of clinical significance.
Addition of this covariate to the model resulted in a modest reduction in interindividual
variability of CL/F. Only a small fraction of patients (5/174) were taking concomitant
rifabutin and it was not possible to obtain conclusive results for the effect of this drug on
the CL/F of nelfinavir.
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INTRODUCTION
Nelfinavir mesylate (Viracept™) is a protease inhibitor approved for the treatment of
Human Immunodeficiency Virus (HIV) infection. The viral protease enzyme plays an
essential role in the replicative cycle of HIV by catalyzing the cleavage of genetically
encoded polyprotein precursors to yield mature, viral proteins (12,21). Inhibition of the
protease enzyme by nelfinavir results in the formation of immature, non-infectious
VlflOnS.

Nelfinavir was approved by the Food and Drug Administration (FDA) in March 1997.
The currently recommended adult dose is 750 mg three times a day (tid) taken with or
after food (1 ). Pharmacokinetic studies of nelfinavir have previously been conducted in
(

phase I/II of clinical drug development (18,20). When nelfinavir was administered at a
dose of 500 mg or 750 mg tid the peak plasma concentration (Cmax) at steady-state was in
the range of 3 - 4 µg/ml and the time to peak concentration (T max) in the range of 2.5 - 3
hours (18). The half-life of nelfinavir has been reported in these studies as 3 - 5 hours
(18 ,20).

Nelfinavir, like the other currently available protease inhibitors, ritonavir, indinavir and
saquinavir, is metabolized by the cytochrome P450 system (13-16,19,20,25,29,31). In
vitro studies have shown that CYP3A4 and CYP2Cl9 are the predominant isozymes
involved (16,29 ,31 ). Other isozymes, CYP2D6 and CYP2C9 are involved to a lesser
extent (11 ,13,25,29). Nelfinavir has one major metabolite, the M8 metabolite (nelfinavir
hydroxy-t-butylamide), which is exclusively catalyzed by CYP2C19 (10,16,29). The M8
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metabolite has been shown to have an antiviral potency in vitro similar to nelfinavir itself
(1 , 15, 16, 1825,31). Studies have demonstrated that CYP2C19 exhibits genetic
polymorphism (17) and that 2 - 6% of Caucasians and 18 - 22% of Asians are poor
metabolizers of CYP2Cl9 (15). In addition to being a substrate, nelfinavir is also an
inhibitor of some CYP450 isozymes, namely CYP3A4, CYP2Cl9, CYP2D6 and
CYP1A2 (13 ,15). Only inhibition ofCYP3A4 appears to be of clinical significance
(13,15) and it seems that nelfinavir is a less potent inhibitor of CYP3A4 than indinavir
and ritonavir (14,15,19,20). It has also been suggested that nelfinavir may induce as well
as inhibit CYP3A4, however, the net effect of nelfinavir on this isozyme appears to be
inhibition rather than induction (15 ,20).

On the basis of nelfinavir ' s involvement with the cytochrome P450 enzyme system, there
is the potential for drug interactions to occur especially as patients with HIV disease are
often taking multiple concomitant medications.

The development of resistance to protease inhibitors, like other antiretroviral therapies, is
of major concern. It has been observed that resistance is more likely to develop when
plasma concentrations of protease inhibitors are subtherapeutic (6). Therefore it is
important to characterize the pharmacokinetics of nelfinavir in a representative patient
population and to try and identify variables that may lead to lower plasma concentrations
which in tum may increase the risk of therapeutic failure .
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Thus, the objectives of this study were to determine the population pharmacokinetic
parameters of nelfinavir and their variability in an HIV infected patient population, to
determine the influence of patient characteristics on the pharmacokinetic parameters of
nelfinavir and to investigate potential drug interactions for an effect upon the
pharmacokinetics of nelfinavir.

METHODS

Concentration-time data were obtained from patients enrolled in a phase III clinical
study, which was primarily designed to evaluate the safety and efficacy of nelfinavir in
HIV infected patients. A secondary objective of the study was to determine the
population pharmacokinetic parameters of nelfinavir. Safety and efficacy results have
been reported elsewhere (5 ,24). This paper deals only with the pharmacokinetic aspects
of the study.

Study Population

The study population included patients aged 13 years or older who had received either no
prior antiretroviral therapy or less than 1 month of treatment with zidovudine (AZT).
Patients were required to have a baseline plasma HIV RNA titer 2: 15,000 copies/ml.
Participants in the trial were randomized to receive nelfinavir 500 mg three times a day,
nelfinavir 750 mg three times a day or placebo. In order to balance treatment groups,
patients' CD4 counts (less than 100 cells per µl, 100 to 300 cells per µl or greater than
300 cells per µl) were used in a dynamic randomization procedure. All patients received
concomitant therapy with AZT 200 mg three times a day and lamivudine (3TC) 150 mg

38

(

twice a day. Concentration-time data were obtained from 174 participants who received
one of the nelfinavir dosage regimens. These patients were enrolled at 27 investigative
sites.

Exclusion criteria at baseline examination included: prior antiretroviral therapy; therapy
with immune modulators or vaccines within one month of baseline; patients of
procreative potential who were not practicing double-barrier contraception; elevated
LFTs, hemoglobin or bilirubin levels; decreased neutrophil or platelet counts; renal
insufficiency; acute pancreatitis or hepatitis; significant fever or diarrhea; malabsorption
syndrome; severe intermittent medical conditions including opportunistic infections;
active substance abuse; neoplastic disease requiring radiation or cytotoxic therapy and
lastly, females taking oral contraceptives. The appropriate institutional review boards
approved the study and written informed consent was obtained from all participants.

Plasma Samples
The pharmacokinetic study was designed such that patients had blood samples drawn for
analysis of nelfinavir concentrations during clinical follow-up visits. In general, each
individual provided two blood samples per visit: a pre-dose trough level and a post-dose
level taken approximately two hours after a dose. The majority of individuals were
sampled at week 2 and week 8 of the study hence all concentrations were considered to
be at steady state. Ultimately, 509 samples from 174 patients were used in the
pharmacokinetic analysis. This was an average of approximately 3 samples per patient
with a range of 1 to 6. Plasma samples were analyzed for nelfinavir and M8
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concentrations using a modified version of a previously published HPLC assay (28). This
assay was modified to include analysis of the M8 metabolite.

Data Preparation and Pharmacokinetic Analysis
Clinical, pharmacokinetic and demographic data relevant to the population
pharmacokinetic analysis were extracted from the raw data and merged and formatted
using SAS (version 6.09) on an IBM ES-9000 computer. The pharmacokinetic analysis
was performed using NONMEM (version 4.0, double precision) (3) on an IBM ES-9000
computer. There are several statistical methods that can be implemented in NONMEM to
calculate parameter estimates (3). Initially, the analyses were performed using the first
order (FO) method and subsequently confirmed using the first order conditional
estimation (FOCE) method.

Pharmacokinetic Model
Several models were used to fit the data. A one-compartment and a two-compartment
open model with first-order absorption and first-order elimination were tested. A zeroorder input to a one-compartment model was also tested using an input period of 3 hours
(the average value of the time taken to reach the maximum concentration previously
reported as 2-4 hours (1)). The first-order input to the one-compartment model was
parameterized as the first order absorption rate constant (ka), oral clearance (CL/F) and
volume of distribution (V/F) and the zero-order input to the one-compartment model was
parameterized as oral clearance (CL/F) and volume of distribution (VIF). The twocompartment model was parameterized as the first-order absorption rate constant (ka),
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oral clearance (CL/F), volume of the central compartment (V c/F), volume of distribution
at steady state (V ss/F) and intercompartmental clearance (Q). The model that best fit the
data was selected for further analyses.

Statistical Model
An exponential error model and a proportional error model were evaluated to describe

interindividual variability. The models were as follows:
8j = 8'exp(lJ9j) - exponential error model, and
8j = 8'*(1 +(ri9.)) - proportional error model
J

where 8j is the estimate for a pharmacokinetic parameter in the j

th

individual as predicted

by the regression model, 8' is the population mean of the pharmacokinetic parameter,
and ri9 . represents the random variable with zero mean and variance o}, that
J

distinguishes the /h individual pharmacokinetic parameter from the population mean
value predicted by the regression model. Terms for interindividual variability were
included in CL/F, V dlF and ka.

Intraindividual (residual) variability was modeled using either a proportional error model
or a combined proportional and additive error model. The following equations were used:
C-·lJ

=

C'·lJ·*(l + i::l lJ··)and
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where Cij is the observed serum concentration for the j

model predicted serum concentration for the j

th

th

individual at time i, C'ij is the

individual at time i, and tlij and i::2ij are

the components of proportional and additive error (with zero mean and variance cr 2 ),
respectively.

Data Analysis Strategy
The pharmacokinetic and statistical models were evaluated to determine the basic model
that best fit the data. A statistically significant decrease in the minimum value of the
objective function (as measured by the Log Likelihood Difference) when comparing
reduced models to fuller models, visual inspection of the data and precision of
pharmacokinetic parameter and variability estimates were used as criteria to determine
the best basic model.

After the basic model was constructed, a model building process was employed to
examine the influence of patient covariates on the estimates of the pharmacokinetic
parameters. The effect of the following patient covariates were evaluated: age, weight,
gender, ethnic origin, dose, baseline HIV disease status, history of liver disease, raised
liver function tests (LFTs), CYP2Cl9 metabolizing status of the patient and concomitant
medications.

Age and weight were examined as continuous variables. Gender, dose, ethnic origin and
history of liver disease were examined as categorical variables. The effect of an increase
in LFTs was examined as a dichotomous variable, either grade two and higher or less
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than grade two. The HIV disease status of the patient at entry into the study was
characterized by baseline CD4 count and baseline viral load. The CD4 count was
categorized into 3 groups as follows: less than 100 cells per µl, 100 to 300 cells per µl or
greater than 300 cells per µI. Viral load measurements were also split into 3 categories:
greater than 100 000 copies/ml, 50 000 to 100 000 copies/ml or less than 50 000
copies/ml. The ability of an individual to metabolize nelfinavir to the M8 metabolite was
investigated as a potential covariate both as a continuous variable and as a categorical
variable. The CYP2Cl9 metabolizing status of the patient was determined, where
possible, from the M8 to nelfinavir peak concentration ratios and categorized into 3
groups. An individual with a ratio of less than 0.1 was classed as a poor metabolizer, an
individual with a ratio of 0.1 to 0.3 as an intermediate metabolizer and an individual with
a ratio greater than 0.3 as an extensive metabolizer (16). As CYP3A4 and CYP2C19 play
an important role in the elimination of nelfinavir (11, 13,31) concomitant medications
known to inhibit or induce these isozymes were examined as potential covariates. The
effects of macrolide antibiotics and quinolone antibiotics were examined as a class rather
than on an individual basis to increase the number of patients in each group. In this study,
patients taking an azole antifungal consisted mainly of patients taking fluconazole, thus,
the effect of fluconazole alone was investigated as was the effect of concomitant therapy
with rifabutin.

A decrease in the minimum value of the objective function of 3.8 or greater following
introduction of a single covariate into the model was considered statistically significant
(p=0.05) using the

x2

distribution if the 95 % confidence intervals (CI) for the estimate
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did not include the null value. If the change in the objective function was 3.8 or greater
but the 95% CI for the estimate included the null value, the effect of the variable was
considered to be of borderline significance and that covariate was not included in the full
model. All significant variables were included in the full model.

A backward elimination process was then employed to eliminate covariates from the full
model in order to develop the final model. An increase in the objective function of 3.8 or
greater (p=0.05) on removal of a covariate from the full model signified that the variable
was important and that covariate was retained in the final model.

Additional Data
It was to prove difficult to obtain accurate estimates of V d/F and ka during this analysis.

To assess the impact of possible misestimation ofVd/F and ka on the ability to estimate
CL/F, the parameter of most interest, Vd/F and ka were fixed to more reliable values and
only CL/F was estimated in the modeling process. Additional data from a traditional
pharmacokinetic study consisting of more samples per individual in a given dosing
interval were analyzed using NONMEM to obtain values for Vd/F and ka. These values
were subsequently used to fix Vd/F and ka in the analysis of the population data. Thus,
analysis of the population data was performed using two models: Model 1 in which all 3
pharmacokinetic parameters were estimated and Model 2 in which fixed estimates of
Vd/F and ka were used.
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Briefly, the data from the traditional study consisted of 190 observations from 19 HIV
infected patients who received nelfinavir monotherapy at doses of 500 mg or 750 mg tid.
Data were obtained from a phase II clinical trial, the results of which have previously
been reported (18). Each patient provided 10 plasma samples at the following times: predose, 0.5 , 1, 1.5, 2, 3, 4, 5, 6 and 8 hours post-dose during a steady-state dosing interval
on day 28 of treatment. No patient was taking a drug that is a known inhibitor or inducer
ofCYP3A4.

RESULTS
The demographic characteristics of the 174 patients in the population analysis are
summarized in Table 1. The mean age (range) was 37 (21-63) years and mean total body
weight was 78 (42-140) kg. The patient population was predominantly male (89%) and
Caucasian (78%).

A one-compartment and a two-compartment model with first-order absorption and frrstorder elimination were used to fit the data. It was not possible to obtain model
convergence when the two-compartment model was fit to the data, thus a onecompartment model was used. The first-order absorption model provided a significantly
better fit to the data as compared to the zero-order absorption model. Thus, the best basic
model consisted of the one-compartment model with first-order absorption and first-order
elimination. Interindividual variability was best described using an exponential error
model and intraindividual variability by a combined proportional and additive error
model.
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As previously mentioned, two models were employed in the analysis, Model 1 in which
all 3 pharmacokinetic parameters were estimated and Model 2 in which V d/F and ka were
fixed to estimates obtained from analysis of the traditional pharmacokinetic data. The
parameter estimates from analysis of the traditional data were as follows: CL/F 39.1 (30.1
- 48.1) L/hr, Vd/F 229 (161 - 297) Land ka 0.845 (0.60 - 1.13) h- 1• Thus Vd/F and ka
were fixed to 229 L and 0.845 h- 1, respectively in Model 2.

The basic pharmacokinetic parameter estimates (and 95% CI) from the fit of Model 1 to
the data were as follows: CL/F 40.7 (37.7 - 43.7) L/hr, Vd/F 731 (531 - 931) Land ka
1.22 (0.70 - 1.74) h- 1• The variability in the estimate of CL/F, expressed as approximate
percent coefficient of variation (%CV), was 36%CV. When a term for interindividual
variability was included in Vd/F, the value tended towards zero. Thus it was not possible
to model interindividual variability in V d/F. A large degree of interindividual variability,
214 %CV was associated with ka. Model 2 provided estimates of CL/F and its variability
of 39.4 (36.3 - 42.5) L/hr and 39% CV respectively. These estimates agreed well with the
estimates obtained using Model 1 and both estimates of CL/F agreed favorably with the
estimate that was obtained from analysis of the traditional data.

Patient covariates that significantly influenced CL/F using both Models 1 and 2 are
shown in Table 2. Neither age, weight, dose level, gender, ethnic origin, baseline viral
load, CYP2C 19 metabolizing status, history of liver disease nor LFTs grade two or
higher appeared to influence CL/F in this group of patients. However, a baseline CD4
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count less than 100 cells per µland concomitant use of either a macrolide antibiotic or
fluconazole resulted in a significant decrease in the estimates of CL/F. The magnitudes of
reduction in CL/F were similar using both models and were 17-19%, 23-24% and 2627% for CD4 count, macrolide or fluconazole use, respectively. A significant increase in
CL/F of 55% was observed in patients taking rifabutin using Model 1. In contrast, a nonsignificant increase of 37% in CL/F was observed using Model 2. Due to the conflicting
evidence of the effect of rifabutin and the small number of patients in the study taking
rifabutin, this covariate was excluded from the model building procedure.

The full model contained all of the aforementioned covariates found to be significant. A
backward elimination process was then employed to eliminate non-significant covariates
(

from the full model to develop the final model. The final model parameters using both
models are shown in Table 3. The equations for CL/F were as follows:
1. Model 1, all parameters are estimated: CL/F = 42.7*(1-0.256*flu) L/hr where flu= 1
if the patient was taking concomitant fluconazole therapy.
2. Model 2, Vd/F and ka are fixed: CL/F = 41.9*(1 -0.273*flu) L/hr where flu= 1 ifthe
patient was taking concomitant fluconazole therapy.

The estimates of CL/F in patients not taking fluconazole were comparable between
models, 42. 7 L/hr and 41.9 L/hr for Models 1 and 2, respectively. Additionally, the effect
of fluconazo le was similar in both models resulting in a reduction in clearance of 26 27%. Interindividual variability in CL/F was reduced marginally from 36% to 34% and
from 39% to 36% in Models 1 and 2, respectively. After controlling for use of
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fluconazole, use of a macrolide antibiotic or a low baseline CD4 count did not
significantly affect CL/F further. Thus it was not necessary to include either of these
covariates in the final model for CL/F.

This data set was also analyzed using the FOCE method in NONMEM. The only
covariate found to be of statistical significance was concomitant use of fluconazole. In
contrast to the FO method, a low CD4 count, concomitant use of a macrolide antibiotic
and concomitant use of rifabutin were either of borderline significance or were not
significant at all when tested alone in CL/F and thus were not included in the full model.
Thus, the final model included only the effect of fluconazole. Parameter estimates for the
final models are shown in Table 4. The estimates of CL/F were 44.9 L/hr and 45 .1 L/hr

(

for Models 1 and 2, respectively. These results compare favorably with the results
obtained from the FO method, 42.7 L/hr and 41.9 L/hr, respectively. Additionally, the
reductions in CL/F observed in patients taking concomitant fluconazole of 26% and 30%
for Models 1 and 2, respectively are in good agreement with the reductions of 26% and
27% obtained using the FO method.

DISCUSSION
The pharmacokinetic parameters of nelfinavir were detem1ined in an HIV infected
population consisting of 174 individuals. A total of 509 plasma concentrations were used
in the analysis. A one-compartment open model with first order absorption and first order
elimination best described the data.
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It proved difficult to obtain accurate estimates of Vd/F and ka in the analysis of this data
set. In previous Phase I studies, V d/F has been estimated as 2-7 L/Kg or 140-490 L in a
70 Kg man (1). The estimate from this analysis was much larger (734 L) and was
associated with large confidence intervals, as was the estimate of ka, which also had a
very large degree of interindividual variability. The ability to estimate pharmacokinetic
parameters well depends upon the timing and number of plasma samples. In this study,
only one early level per dosing interval was taken in each individual. This level was taken
at essentially the same time in every individual, two hours after the dose. This is close to
the reported Tmax of nelfinavir (2.5-3 hours) (18), a period of the concentration-time
profile associated with inherent variability as plasma concentrations change markedly . It
is likely that this inherent variability in observed plasma concentrations within an
individual, the lack of variability in the timing of the early post dose levels between
individuals and the small number of early samples per individual (typically 2 overall)
made it impossible to obtain accurate estimates of Vd/F and ka. Additionally, the
difficulty in estimating these parameters may be compounded by the lack of information
in the data set on factors that can influence the absorption and/or bioavailability of
nelfinavir. Studies have demonstrated that the Cmax and AUC of nelfinavir are 2-3 times
higher in fed versus fasted subjects (1 ,22). Unfortunately, the timing of the dose relative
to meals was not controlled in this study. Also, the bioavailability of protease inhibitors
in general has been found to be sensitive to other physiological factors, such as gastric pH
(2,26). Due to the problems encountered in estimating V d/F and ka in this particular data
set, the estimates that were obtained should be interpreted with caution. Estimation of
these parameters should be made in the future using more informative data.
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In order to assess any influence of misestimation ofVd/F and ka on the estimation of
CL/F, two models were used in the analysis. In Model 1, all 3 parameters (CL/F, Vd/F
and ka) were estimated. In Model 2, the values ofVd/F and ka were fixed to estimates
obtained from analysis of traditional pharmacokinetic data obtained from 19 individuals
with HIV infection (229 Land 0.845 h- 1 for Vd/F and ka, respectively). The estimates
obtained for CL/F and the influence of fluconazole on CL/F were in good agreement
between the models. This provides support that estimation of CL/F and the evaluation of
the effect of covariates on CL/F were not affected by possible misestimation ofVd/F and
ka. Wade et al. previously investigated the effect of misspecification ofka on the ability
to estimate CL using sparsely sampled simulated data (27). They found that
misspecification of ka did not markedly affect the ability to estimate CL. The estimates
obtained for CL/F were 42.7 L/hr and 42.0 L/hr using Models 1 and 2, respectively.
These values compare favorably with previous estimates of the CL/F ofnelfinavir of 37.4
L/hr (30) and 46.0 L/hr (calculated as Dose/AUC 0 _8h) (18).

Azole antifungal agents are commonly prescribed for patients with HIV disease for the
treatment and prophylaxis of fungal infections (9). In this study, 25of174 patients (15%)
were receiving concomitant azole therapy. Since 23 of these 25 patients were taking
fluconazole, it was only possible to assess the effect of this azole antifungal on the CL/F
ofnelfinavir. Fluconazole is a known inhibitor of CYP3A4 and CYP2C19, the primary
isozymes involved in the metabolism of nelfinavir (29,31 ). This study found that patients
receiving concomitant therapy with fluconazole experienced a statistically significant

50

(

reduction in CL/F of 26-27% compared to patients not taking fluconazole. However, it is
unlikely that an effect of this magnitude would be clinically significant and warrant
dosage adjustment. A similar decrease in CL/F was observed in a study of 8 healthy
volunteers treated with ritonavir who received concomitant fluconazole therapy (4). The
authors found that fluconazole produced marginal increases ofless than 15% in the
AUCo-Z4h and Cmax of ritonavir (4). In contrast, in a study conducted in 11 HIV-infected
patients receiving indinavir, investigators found that concomitant fluconazole therapy did
not result in a reduction in the CL/F of indinavir. Indeed, they found a slight decrease in
AUCo-sh of indinavir that failed to achieve statistical significance (7). The different
metabolic pathways of these protease inhibitors may account for the inconsistency of the
results.

(

Concomitant use of a macrolide antibiotic and a baseline CD4 count less than 100 cells
per µl were statistically significant covariates for CL/F when tested alone (Table 2).
However, the influence of concomitant fluconazole therapy was greater and once this
effect had been incorporated into the final model for CL/F, the effects of concomitant use
of a macrolide antibiotic and a low baseline CD4 count were no longer statistically
significant. It should be noted that 16 of the 35 patients with a low CD4 count were
taking fluconazole and 8 of the 18 patients receiving concomitant macrolide therapy were
also taking fluconazole. Thus, the observed influence of a low CD4 count and
concomitant macrolide therapy may be explained by the high percentage of patients with
these characteristics who were also taking fluconazole.
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In this study, the CYP2C19 metabolizing status of the patient was characterized by the
M8 to nelfinavir peak concentration ratio. A patient with a ratio ofless than 0.1 was
classed as a poor metabolizer. It has previously been reported that patients classed as
poor metabolizers have a lower M8/nelfinavir ratio than either intermediate or extensive
metabolizers (16). This is probably due to a reduction in CL/F. However, the small
number of poor metabolizers identified in this study (n=6) may have prohibited the
detection of a significant effect upon CL/F.

The effect of rifabutin on the CL/F of nelfinavir was inconsistent using the models in this
analysis. It is probable that this study did not have sufficient power to assess the influence
of rifabutin on the CL/F of nelfinavir, since only 5 of the 174 patients in the study were
taking rifabutin. In both models, there was a trend for concomitant rifabutin to increase
the CL/F of nelfinavir (from 37-55%). However, only when all three pharmacokinetic
parameters were estimated did the increase achieve statistical significance. There is
evidence from other clinical sh1dies that rifabutin induces the metabolism of nelfinavir
(1). In one study, concomitant administration of rifabutin decreased the AUC and Cmax of
nelfinavir by 32% and 25%, respectively (1).

The FO method in NONMEM involves linear assumptions that the FOCE method does
not which increases the risk of obtaining biased parameter estimates. However, the FOCE
method is computationally more complicated than the FO method, resulting in a
substantially longer time to run an analysis. A limited comparison of some linear
approximation methods (e.g. the FO method) with computationally more intensive
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approximation methods (e.g. FOCE method) has shown that the linear approximation
methods perform adequately (23). In this study, the population pharmacokinetic
parameters were obtained initially by implementing the FO method in NONMEM and the
results confirmed using the FOCE method. The final models using both methods did
compare favorably showing that, in this instance, the FO method provided adequate
estimates. Overall, the estimates of CL/F (ranged from 41.9 L/hr to 45.1 L/hr) and the
effect of fluconazole on CL/F (reduction in CL/F of26% - 30%) were similar. However,
the FOCE method proved to be more discerning in that it did not initially identify the
covariates identified by the FO method as statistically significant alone (low CD4 count
and concomitant use of a macrolide antibiotic or rifabutin) that were subsequently
dropped during the final model building process due to lack of significance.

(

In conclusion, the population pharmacokinetic parameters of nelfinavir were best
described using a one-compartment model with first-order absorption. Estimation of
V d/F and ka was difficult using this data and the values obtained should be interpreted
with caution. CL/F was estimated as 42. 7 L/h (Model 1) and 41 .9 L/h (Model 2). Patients
receiving concomitant therapy with fluconazole had a 26-27% reduction in CL/F. A
reduction of this magnitude is unlikely to be of clinical significance. The study probably
did not have sufficient power to assess the influence of concomitant rifabutin. However,
the consistent though statistically insignificant increased CL/F observed among patients
taking rifabutin in this study is in keeping with evidence of an interaction from previous
studies.
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Table 1: Characteristics of 174 Patients Evaluated in the Population
Pharmacokinetic Analysis of Nelfinavir

Characteristic

Gender (Men/ Women)
Mean Age, years (range)

Number

Percent of Total

of

Study

Patients

Po~ulation

155/19

89/ 11

37 (21-63)

Mean Total Body Weight, kg (range)
Baseline CD4 Count (cells per

77.7 (42-140)

~Li)

< 100

35

20

< 300 and > 100

59

34

> 300
Baseline Viral RNA (copies /ml)

80

46

> 100,000

68

39

> 50,000 and < 100,000

43

25

63

36

136

78

Black

21

12

Asian

3

2

Hispanic

7

4

Latin American

4

2

Native American

3

2

< 50,000
Race,
Caucasian

Concomitant Medications
Azole (fluconazole)

25 (23)

15 (13)
10

Macrolide

18

Quinolone

12

8

Rifabutin

5

3

History of liver disease

60

34

Liver function tests (LFTs) grade 2 or higher

51

29

Poor Metabolizer (ratio < 0. 1)

6

3

lntermediate Metabolizer (ratio > 0. 1 and < 0.3)

67

38

Extens ive Metabolizer (ratio > 0.3)

37

21

Metabolic Status (Ratio of nelfinavir: M8)

60

,,,...--

~

Table 2: Summary of Analyses of Significant Effects of Patient Covariates tested alone in Clearance
Hypothesis

Significance•

Parameterization

Null
Value

Parameter Values
(95%C.!}

Change in
objective function

CL/F=81 *(1-84*cd4)

0

84 = 0.19 (0.02, 0.36)

10.0 14

Significant

CL/F=81 *(l-84*flu)
CL/F=81 *(l-84*mac)
CL/F=81 *(l-84*ri:t)

0
0
0

84 = 0.26 (0.11, 0.40)
84 = 0.24 (0.02, 0.46)
84 = 0.55 (0.32, 0.77)

17.225
10.784
6.035

Significant
Significant
Significant

CL/F=81 *(1-84*cd4)

0

84 = 0.17 (0.01 , 0.33)

6.978

Significant

CL/F=81 *(l-84*flu)
CL/F=81 *(l-84*mac)
CL/F=8I*(1-84 *ri:t)

0
0
0

84 = 0.27 (0.15, 0.40)
84 = 0.23 (0.06, 0.41)
84 = 0.37 (0.17, 0.57)

18.53 1
10.132
3.012

Model One

•Do the following affect CUF?
CD4 < 100 cells per µ1
Concomitant Medications
Fluconazole
Macrolide
Rifabutin
Model Two
0\

........

•Do the fo/lowi ng affect CUF?
CD4 < I 00 cells per µl
Concomitant Medications
Fluconazole
Macrolide
Rifabutin

Significant
Significant
Not Significant

p = 0.05
Abbreviations: CL/F =clearance: LLD= log-likelihood difference; NA= not applicable; flu = concomitant fluconazole therapy;
mac= concomitant macrolide therapy; rif = concomitant rifabutin therapy.
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Table 3: Final Population Pharmacokinetic Parameters for Model 1 and Model 2
(First Order Method)
Model 2•

Model 1•
Parameter

Parameter

lnteq1atient

Parameter Estimates

Interpatient

(units)

Estimates (95% CI)

Variabilityb

(95% CI)

Variabilityb
(95% CI)

(95% CI)
8lcL/hr

42.7 (39.3 - 46.1)

34 (27 - 39)

41.9 (38.7 - 45 .1)

36 (28 - 43)

82 (Vd/F) L

736 (501-971)

NI

229 fixed

81 (65 - 94)

83 (ka) h-1

1.19 (0.200 - 2.18)

142

0.845 fixed

NI

94c

0.256 (0.111 - 0.401)

cr2 1

0.106 (0.028 - 0.184)

NA

0.025 (-0.015 - 0.064)

NA

cr2 2 (mg/L)

0.265 (0.014 - 0.516)

NA

0.537 (0.300 - 0.778)

NA

0.273 (0.150 - 0.396)

• Model l - all 3 parameters are estimated; Model 2 - Yd and ka fixed to 229 Land 0.845h-1, respectively.
b

approximate coefficient of variation (%CV)
c CL/F = 8 l *(1- 84*flu) L/hr where flu= l if the patient was taking concomitant fluconazole therapy, else
flu=O .
Abbreviations: CL/F = clearance; Vd/F = volume of distribution; ka = absorption rate constant; cr 2 l =
variance of proportional component of residual error; cr2 2 = variance of additive component of residual
error; NI= Not Identifiable; NA= not applicable
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Table 4: Final Population Pharmacokinetic Parameters for Model 1 and Model 2
(FOCE Method)
Model 2a

Model la
Parameter

Parameter

Interpatient

Parameter Estimates

lnterpatient

(units)

Estimates (95% CI)

Variabilityb

(95% CI)

Variabilityb
(95% CI)

(95% CI)

(

81CL/hf

44.9 (40.9 - 48.9)

34 (28 - 40)

45.1 (41.6-48.6)

34 (27 - 39)

82 (Vd/F) L

769 (363 - 1175)

53

229 fixed

99 (76 - 117)

83 (ka) b-I

1.34 (-1.76 - 4.44)

58

0.845 fixed

NI

84c

0.26 (0.13 - 0.40)

cr2 1

0.090 (-0.001 - 0.18)

NA

0.035 (-0.005 - 0.075)

NA

cr 22 (mg/L)

0.28 (0.003 - 0.55)

NA

0.47 (0.28 - 0.66)

NA

0.305 (0.181 - 0.429)

• Model 1 - all 3 parameters are estimated; Model 2 - Yd and ka fixed to 229 Land 0.845h- 1, respectively.
b

approximate coefficient of variation (%CV)
c CL/F = 81*(1-84*flu) L/hr where flu=l if the patient was taking concomitant fluconazole therapy, else
flu=O.
Abbreviations: CL/F = clearance; Vd/F = volume of distribution; ka = absorption rate constant; cr2 l =
variance of proportional component of residual error; cr2 2 = variance of additive component of residual
error; NI= Not Identifiable; NA= not applicable

(
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MANUSCRIPT ID
Design of Population Pharmacokinetic Studies Utilizing Sparse Data.
*presented at the AAPS 13 111 Annual Meeting, San Francisco, November 1998.
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ABSTRACT
Simulation studies are useful tools to investigate issues of study design when planning a
prospective pharmacokinetic analysis of sparsely sampled data. In this study simulated
data was used to investigate different study designs consisting of 2 samples per individual
and to investigate the influence of different sizes of a sub-population on the ability to
detect that sub-population. A one-compartment model with intravenous input was used .
Two levels of interindividual variability were investigated (30% and 60%),
intraindividual variability was fixed at 25% and the sub-population had a 30% reduced
value of clearance (CL).

The ability to detect the sub-population and to obtain accurate parameter estimates
deteriorated when interindividual variability was increased from 30% to 60%. When
interindividual variability was low (30%), a sub-population in which the average value of
CL was 30% lower than in the general population, could be identified. However, none of
the designs studied here could consistently identify the sub-population when
interindividual variability was high (60%). In general, estimates of pharmacokinetic
parameters were more precise and less biased than estimates of the variability parameters.
Accurate pharmacokinetic parameter estimates could be obtained using some of the
designs at both levels of interindividual variability. In contrast, variability parameters
were unacceptable using all of the designs when interindividual variability was high. The
performance of one design, which consisted of three sampling windows covering the
whole dosing interval, was superior to the other designs investigated.
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Other design factors such as the total sample size, the level of intraindividual variability
and the use of a different algorithm in NONMEM to estimate parameters were evaluated
to see if the study design could be further improved upon. This was carried out at the high
level of interindividual variability. Although modification of some of these factors did
result in improvement in both the ability to detect the sub-population and in the accuracy
of parameter estimates, it was still not possible to accurately estimate all of the variability
parameters using a 2 sample per individual design.
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INTRODUCTION
The population approach to pharmacokinetic analysis involves estimating
pharmacokinetic parameters and their variability within a study population and evaluating
the effect of demographic and physiological characteristics of the population on the
pharmacokinetic parameters (1 ). This approach can be used to analyze sparsely sampled
data from observational studies (2-4). A number of recent articles in the literature have
reviewed this topic (5-9) illustrating the considerable interest in the application of this
approach. Additionally, in February 1999, the Federal Drug Administration (FDA) issued
a guidance document for the pharmaceutical industry concerning population
pharmacokinetic studies (10). This document provides recommendations on the design,
conduct, analysis and reporting of population pharmacokinetic studies from a regulatory
perspective.

As previously mentioned, the population approach can be used when only sparsely
sampled data are available. When data are sparse the design of the study is important if
accurate parameter estimates are to be obtained (6, 11). Issues such as the timing of
samples, the number of samples per individual, the total number of individuals required
for a population analysis and the quality of the data need to be addressed .

An example in which the population approach can be effectively implemented is in the

analysis of sparse data collected during large phase III clinical trials (12). It is of
paramount importance that population analyses that are designed to be incorporated into
these studies should impinge upon the primary objective(s) of the clinical study as little
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as possible (13). As the total number of subjects in the study will most likely be dictated
by the primary objective(s) of the clinical trial this is not an aspect of the study design
that can be controlled. On the other hand, the number of samples per subject and the
timing of samples are issues that should be considered when designing the study. To
encourage good compliance with the study protocol it is important to consider factors
such as the time spent by clinical investigators, the time spent by the patients in the clinic
(these studies are mainly conducted on an out-patient basis) and the additional cost of
assaying samples (6) . For these reasons, a study design that involves taking as few
samples as possible from each individual is preferable.

Several investigations of design issues of population pharmacokinetic studies have been
reported in the literature using simulated data (3 , 11 ,14-23). Many different designs have
been evaluated such as designs including only 1 sample per individual, designs using a
one or two-compartment model, and designs using intravenous or oral input. At least 2
samples per individual are necessary if the approach is to identify intraindividual
variability and distinguish it from interindividual variability. Thus, if we could assure that
the quality of the results obtained are not compromised, a 2 sample per individual design
for a one-compartment model with intravenous input would be a good choice.

An important application of the population approach is to evaluate the effect of patient
covariates on the pharmacokinetic parameters within the study population. Techniques
have been proposed on how best to build a population model to include the effects of
covariates that may significantly influence pharmacokinetic parameters and explain
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variability (24,25). However, there is very little information in the literature pertaining to
the size of a sub-group (possessing the covariate of interest) necessary to successfully
detect the effect of that covariate. In 1985, Sheiner and Benet published one of the
earliest papers that specifically addressed the design of population pharmacokinetic
analyses in drug development trials (1 ). They took an empirical approach and suggested
that when the full pharmacokinetic screen is implemented (i.e. several samples are taken
per individual at different times after a dose) then 10-20 individuals in a sub-group would
suffice and a total of 50 - 100 individuals would be adequate to establish the population
pharmacokinetics of a drug. This issue was also addressed at an expert meeting on the
design and conduct of population pharmacokinetic studies held in Europe in 1995 (13).
Again 20 individuals were proposed for the size of a sub-group based upon the

(

experiences of the individuals present. Vozeh et al. suggested that even as few as 10
individuals in a sub-group would be sufficient in some cases to detect the effect of that
sub-group (6). In contrast, Breant and colleagues found that to detect a sub-population
with altered pharmacokinetics within their data set, they required approximately 40
patients and 4 - 5 blood levels per patient (26). None of these papers specifically
addressed the magnitude of the effect to be identified, although it was stated that
decisions should be made on a case by case basis (13).

Thus, the objectives of this study were i) to determine if accurate parameter estimates
could be obtained using different study designs consisting of only 2 samples per
individual, ii) to evaluate the influence of the size of a sub-group with a 30% reduced
clearance on the ability to consistently identify that sub-group, and iii) to evaluate the
\
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influence of the size of a sub-group on the ability to estimate pharmacokinetic and
variability parameters in both populations.

METHODS:
Pharmacokinetic Model
Data were simulated based upon the population pharmacokinetic parameters of
theophylline. The values used were 2.94 L/hr for clearance (CL) and 31.5 L for volume
of distribution (V d) (27, 28). A one-compartment model with intravenous bolus input was
used . Plasma concentrations were simulated following a single dose of 300mg.

Statistical Model
Interindividual variability in both CL and V d were modeled using an exponential error
model :
8j = 8'*exp(rie.))
J

where 8j is the estimate for a pharmacokinetic parameter in the jth individual as predicted
by the regression model, 8' is the population mean of the pharmacokinetic parameter,
and rie . represents the random variable that distinguishes the jth individual
J

pharmacokinetic parameter from the population mean value predicted by the regression
model. It was assumed that rie. is a normally distributed random variable with zero mean
J

and variance ro 2 .

Intraindividual (residual) variability was also described using an exponential error model:
Cij = C'ij *exp(Eij)
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where Cij is the observed serum concentration for the jth individual at time i, C'ij is the
model predicted serum concentration for the jth individual at time i, and Eij is the residual
error that represents the difference between the observed concentration and the model
predicted concentration. Eij was assumed to be normally distributed with zero mean and
variance cr2 .

Variability in interindividual variability and intraindividual variability will be represented
by their standard deviations which are COcL, co vd and cr for interindividual variability in
CL, interindividual variability in Vd and intraindividual variability, respectively. When
the logarithmic model is used to describe either interindividual or intraindividual
variability, co and cr may be regarded as approximate coefficients of variation.

Data
Data were simulated for 100 individuals each of whom contributed two plasma
concentrations. Thus, one data set consisted of 300 observations, 200 plasma
concentrations and 100 dosing records. The 100 individuals comprising a data set
possessed one of two sets of pharmacokinetic parameters. Individuals in Group A had a
" normal" population value of CL of 2.94 L/hr and a V d of 31. 5 L whereas individuals in
the sub-group, Group B, had the same population value for V d but a reduced value for
CL of2.06 L/hr. This corresponds to a reduction in CL of 30%. A clinical example where
this may occur is in the case of a drug interaction in which a concomitant medication
inhibits the metabolism of the study drug causing a reduction in the value for CL.
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Different ratios of individuals in Group A and Group B were used to investigate the
influence of the size of the sub-group on the ability to detect that sub-group accurately
and to estimate the pharmacokinetic and variability parameters in both groups. The ratios
of patients in Group A to Group B were varied as follows : 90: 10, 80 :20 and 70 :30 for
Groups A and B, respectively.

Sampling Schedules
Initially, D-optimal sampling as implemented in ADAPT (29) was used to identify the
two optimal times to sample based upon a one-compartment intravenous input model.
They were determined as being as early as possible and as late as possible after a dose.
To mimic a real life situation in which it is unrealistic to take samples at exactly the same
time for each individual, a randomized informative block design was used consisting of
sampling windows (18) . Three designs that used different sampling windows to obtain
the two samples for each individual were evaluated. The sampling windows for each
design are shown in Table 1. In Design 1, all patients had the early sample taken between
0.08 and 1 hour, and a late sample taken between 7 and 8 hours after the dose. Similarly,
in Design 2 all individuals were sampled between 0.08 and 1 hour, and then between 8
and 24 hours. In Design 3, the complete dosing interval was split into 3 blocks: the first
block from 0.08 to 1 hour, the second block from 1 to 8 hours, and the third block from 8
to 24 hours. Each individual was sampled from two different time blocks. The ratio of
total samples in the data set was approximately 1: 1: 1 from each block.
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Data Simulation
For each of the 100 individuals in a data set, 2 random time points from within the
appropriate sampling window were generated in Excel. Data were simulated using the
computer program NONMEM (Non-linear Mixed Effects Modeling) (version 4.0, double
precision) (30) on an IBM ES-9000 computer. For each scenario, 100 data sets were
replicated .

The influence of interindividual variability on the pharmacokinetic parameters was also
investigated. The study was carried out in the presence of two levels of interindividual
variability in both CL and Vd, a low level of variability of 30% and a moderately high
level of variability of 60%. In all cases intraindividual variability was set at 25% . A total
of 1800 data sets were simulated.

(
Effect of Changing Intraindividual Variability
To investigate the influence of a lower level of intraindividual variability on the ability to
obtain accurate parameter estimates, Design 3, where the ratio of patients in group A to B
was 80:20, was repeated using an intraindividual variability of 15% (Design 4). This was
done in the presence of interindividual variability of 60%.

Effect of Changing Total Sample Size
The effect of increasing the total sample size was investigated using Design 3 where the
ratio of patients in group A to B was maintained at 80 :20. The total sample was increased
from 100 individuals to 200 individuals (Design 5). Thus, the data set used in Design 5
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consisted of 160 individuals who were sampled from Group A and 40 who were sampled
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from group B. This was done in the presence of interindividual variability of 60% and
intraindividual variability of 25%.

Data Analysis
For each simulated data set, estimation of pharmacokinetic and statistical parameters was
carried out using NONMEM. Each simulated data set was analyzed using two models i) a
basic model in which there was no attempt to distinguish between patients from Groups
A and B and ii) a more complex model (full model) in which an additional parameter was
included to distinguish between patients in Groups A and B. A drop in the objective
function of 3. 84 or greater when comparing the full model to the basic model was
considered statistically significant (p=0.05). In these instances it was concluded that a
(
'.

sub-group possessing a reduced value of clearance had been identified using NONMEM.
Only runs that successfully identified two groups of patients were used to determine the
accuracy of parameter estimates. The estimation procedure was run in NONMEM using
the first order (FO) method .

FO versus FOCE Method
A number of different methods of calculating parameter estimates can be used in
NONMEM (30). The first order (FO) method uses a first order approximation method
that involves linearization of the random effect parameters. This algorithm may produce
more biased estimates than the first order conditional estimation (FOCE) method . To
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compare the use of these two mathematical algorithms, Design 3 where the size of Group
B was 20 was repeated using the FOCE method (Design 6) and the results compared.

Bias and Precision of Parameter Estimates
The accuracy of the estimates from each data set were evaluated using the
percent prediction error (%PE) as described by the following equation:

%PE = (Ssim - Strue)/ Stme * 100

where Strue is the true population value for the parameter and Ssim is the estimated
population value of the parameter from one simulated data set. The %PE was calculated
for the 100 simulated datasets in each scenario. The mean %PE was used as a measure of
bias and the standard deviation (SD) of %PE was used as a measure of the precision of
parameter estimation. Previous simulation studies have regarded different magnitudes of
bias and precision as being acceptable (11 , 17,18,22). In this study, the following
guidelines were employed : a mean %PE for a
unbiased and a SD of%PE

~

parameter ~

15% was accepted as being

35% was accepted as being precise (17).

RESULTS
The percentage of runs in which individuals sampled from Group B were successfully
identified using the various designs are listed in Tables 2 and 3 and illustrated in Figures
la and lb. Figure la represents the results when interindividual variability was set at 30%
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and Figure 1b represents the results when interindividual variability was set at 60%. The
following results were obtained on analysis of the data:
1. The number of runs where Group B was successfully identified was greater for all
designs when interindividual variability was 30% as compared to 60%.
2. Both Designs 2 and 3 performed better than Design 1 when interindividual variability
was 30% but not when interindividual variability was 60%.
3. In general, using all of the designs, when the size of Group B was increased from 10
to 20 there was marked improvement in the ability to detect Group B. Increasing the
size of Group B from 20 or 30 did not offer the same improvement.

For Designs 1 to 3, bias and precision of pharmacokinetic parameter estimates are shown
in Tables 4 and 5 and Figures 2 and 3 when interindividual variability was 30% and in

(
Tables 6 and 7 and Figures 4 and 5 when interindividual variability was 60%. Bias and
precision of variability parameter estimates are shown in Tables 4 to 7 and Figures 6 to 9.

Looking at the pharmacokinetic parameter estimates first, when interindividual variability
was 30%, all 3 pharmacokinetic parameters were acceptable in terms of bias and
precision regardless of the design used or the sizes of Group B. When interindividual
variability was 60% only Design 1 failed to give acceptable estimates. Only the estimate
of CL of Group B was biased when Group B consisted of 10 individuals. Otherwise,
using the other designs, all pharmacokinetic parameters were estimated accurately.
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In general, variability parameters were less well estimated than the pharmacokinetic
parameters. When interindividual variability was set at 30% (Table 4, Figure 6), Design 1
performed adequately in terms of bias at all levels. Using Design 3, estimates of cocL and
co vd were acceptable but estimates of CT were slightly biased. Using Design 2, biased
estimates of nearly all of the parameters were obtained regardless of the size of Group B.
However, there was a trend for bias to improve as the size of Group B increased using
Design 2.

The situation with respect to precision was different. All levels of both Designs 1 and 2
produced imprecise estimates of variability parameters although COcL was measured
precisely using Design 2. There did not appear to be an improvement in precision of the
r

parameter estimates as the size of Group B increased. Using Design 3, estimates were in

\

general more precise than estimates obtained with the other designs but in no case did
Design 3 produced precise estimates of all 3 variability parameters. However, when
parameters were found to be imprecise they were only just above the upper limit of
acceptability.

When interindividual variability was set at 60%, all designs performed worse than at
30%. In fact, no design provided estimates of the pharmacokinetic parameters that were
acceptable in terms of either bias or precision. Taking Design 1 first, COcL and covd were
unbiased when group B consisted of20 or more individuals but these estimates were
imprecise. Estimates of CT were biased and imprecise in all cases. Bias and precision of
some parameter estimates deteriorated as group B got larger. Using Design 3, estimates
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of CDcL were unbiased only when the size of Group B was 30. Estimates of ro v d were
unbiased regardless of the size of Group B. Conversely, a was biased in all cases. In
terms of precision, estimates of CD cL were only marginally imprecise and when Group B
consisted of 20 individuals the estimates of both ro cL and ro v d were acceptable although
the estimate of a in this scenario was more imprecise as compared to the other cases.
There does not appear to be an obvious trend in the level of imprecision using Design 3.
Design 2 produced the most biased estimates. In fact, all parameters were biased
regardless of the size of Group B and the estimates of a were enormously biased, in the
magnitude of300% in each case. However, in terms of precision, Design 2 performed
comparably to Designs 1 and 3. Estimates of both CDcL and ro v d were acceptable except
ro vd when

Group B was 30, which was only marginally imprecise. Estimates of a were

highly imprecise at all levels and like Design 3 there did not appear to be a definite trend
in precision as the size of Group B varied.

Effect of Changing Intraindividual Variability
The influence of the level of intraindividual variability within the data was investigated .
The original simulations were conducted using a level of 25% (Design 3). To investigate
the effect of a lower level , the study was repeated where intraindividual variability was
reduced to 15% (Design 4). The results using Designs 3 and 4 are shown in Table 8 and
Figures IOa and I Ob. In terms of bias and precision, reducing intraindividual variability
from 25% to 15% did not affect the estimation of the pharmacokinetic parameters or the
interindividual variability parameters. The only noticeable effect was upon the estimates
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of intraindividual variability. When intraindividual variability was lower, estimates of CT
were both more biased and less precise.

Effect of Changing Total Sample Size
The results of increasing the total sample size from 100 individuals (Design 3) to 200
individuals (Design 5) are shown in Table 9 and Figures 1 la and 11 b. Using Design 5,
the estimate of roCL was unbiased and estimation of CL of Group B, ro vd and

CT

were

improved. In terms of precision, the biggest change was in the precision of CT which was
much improved using Design 5 but still not acceptable. The estimate of rovd was
marginally worse with Design 5 but still within the acceptable limits.

(

FO versus FOCE Method
The results comparing the FO method (Design 3) to the FOCE method (Design 6) are
shown in Table 10 and Figures 12a and 12b. Unbiased and precise estimates of all 3
pharmacokinetic parameters were obtained using both methods. Variability parameters
were less biased and more precise using the FOCE method. Only

CT

was biased using the

FOCE method . The FO method produced an imprecise estimate of CT whereas all 3
variability parameters were precise using the FOCE method .

DISCUSSION
The population approach to pharmacokinetics is used to obtain estimates of the
pharmacokinetic parameters and their variability within a population. The approach is
versatile in that it can be applied in a variety of different situations e.g. when data is rich,
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when data is sparse or when a combination of the two kinds of data is available. In the
case of phase III clinical trials, when data is sparse and there is a large, heterogeneous
population in comparison to the populations of traditional studies, more realistic
estimates of the variability of the parameters can be obtained. Patient specific parameters
such as demographic characteristics or physiological variables can be evaluated as
potential sources to explain some of the variability. In this way, the behavior of the drug
in different populations can be characterized and the need for dosage adjustment
addressed. When data are sparse, particular attention must be given to the design of the
study as good quality results can only be achieved if good quality data are available.
There are many factors that are influential and should be taken into consideration when
the study is being planned. These include the pharmacokinetic characteristics of the drug
under study, the primary objectives of the study, the timing and number of samples, the
heterogeneity of the study population and the cost of collecting and analyzing the
samples. Another consideration to take into account is the size of a sub-population
possessing a characteristic that is to be evaluated for an effect upon a pharmacokinetic
parameter. If an effect is to be detected then the sub-population must be of sufficient size
to provide the study with the power to detect this effect. Simulation studies are ideal tools
to investigate these types of issues prior to execution of the study. Different designs can
be investigated to determine the optimal design for a given situation.

In this study, data were simulated using a one-compartment model with intravenous input
according to various study designs. Initially 3 designs were evaluated . Each design
comprised 2 samples per individual and 100 individuals. In Design 1 the samples were
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taken between 0.08 and 1 hour and between 7 and 8 hours, in Design 2 they were taken
between 0.08 and 1 hour and 8 and 24 hours and in Design 3 each individual contributed
2 samples from 2 of the following 3 sampling windows: 0.08 to l hour, l to 8 hours and 8
to 24 hours. Additionally, different combinations of individuals were used to make up the
study population. Individuals could be sampled from one of two groups, Group A where
the population average value of CL was 2.94 L/hr and Group B where the population
average value of CL was 2.06 L/hr. The Group B average value represents a 30%
reduction in CL. The efficiency of the different study designs in obtaining accurate
parameter estimates was evaluated.

First, the ability to identify the sub-population was investigated. When interindividual
variability was low, the performance of Design 1 was substantially worse than Designs 2

(
and 3 in identifying Group B. In order to detect group B, where the population average
value of CL is reduced, the study design must provide informative data about CL. The
half-life of the drug in this study was 7.4 hours. Using Design 1, the late sample was
taken between 7 and 8 hours after administration of the drug i.e. approximately one halflife after dosing. Ette et al used a single sample per individual design and found that
when the late sampling point was approximately one half-life after dosing, performance
of the study design was worse than when the sample was taken at a later time (19). They
found that the optimal time period to gain information about CL was 1.4 - 3 half-lives
after administration of the drug. The results observed in this study are consistent with this
observation which suggests that Design 1 performed badly because it did not contain
enough relevant information to obtain accurate estimates for CL of either group A or
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group B . On the other hand, Designs 2 and 3 did contain information within the optimal
period to estimate CL and thus these designs performed better.

At a level of 30% interindividual variability, increasing the size of Group B from 20 to 30
individuals did not improve upon the ability to detect Group B . Thus, the previously
suggested size of a sub-population of 20 (1 , 13) appears to be acceptable to detect a 30%
or greater change in CL when interindividual variability is low.

In the case of rugh interindividual variability (60%), it became substantially more
difficult to detect group Busing all designs. In fact, none of the designs were consistently
able to detect the sub-population. Even when the size of the sub-population was 30, the
number of runs in wruch the sub-population was successfully identified was only 60 to
(

70% for the various designs. In contrast to the performance observed when
interindividual variability was low, increasing the size of Group B from 20 to 30
individuals resulted in marked improvement in detecting group B for Designs 1 and 3.
Design 1 performed better than Designs 2 and 3 in detecting the sub-group when the size
of the sub-group was 30, 69% detected versus 59% and 62% for Designs 2 and 3,
respectively. There is no obvious reason why this would be the case and it may just be a
spurious finding considering the overall low performance of all designs.

None of the study designs investigated here were adequate when variability was high. A
study by Breant et al used real data on cyclosporine where

WcL

was approximately 30 -

40% and ro vd was 60- 100%. They investigated the effect of sample size on the ability to
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accurately determine the pharmacokinetic parameters of a one-compartment model (26) .
By stepwise addition of 1 sample at a time starting from just 1 sample in 1 patient they
found that parameter estimates tended to converge when 10 - 20 patients contributed 2 4 blood samples each. However to detect a sub-population with altered pharmacokinetics
they required more patients and more samples per patient (approximately 40 patients and
4 - 5 blood levels per patient). A drawback to their study was that an optimal sampling
strategy was not employed in selecting the blood levels. The lack of planned sampling
times and the small number of subjects in total may have contributed to the large number
of samples required per individual to detect the sub-population. The situation in this study
was similar in that none of the 2 sample designs investigated performed adequately.
Consequently, more samples per individual may be required to detect a 30% reduction in
CL when interindividual variability is 60% or higher. Under these circumstances, the
previously reported size of 20 for a sub-population would not be sufficient.

An alternative approach to increasing the number of samples per individual may be to

increase the total size of the study population. This was investigated using Design 3 (100
individuals) and Design 5 (200 individuals) . The percentage of individuals in group B
was maintained at 20% and interindividual variability was set at 60%. Increasing the
total sample size resulted in marked improvement in the ability to detect the subpopulation. The percentage of runs in which group B was successfully identified
increased from 49% to 80%. Thus, increasing the total number of individuals in the study
population yet maintaining the number of samples per individual at 2, aided in identifying
the sub-group.
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When interindividual variability was 60% and either intraindividual variability was
reduced to 15% or the FOCE method was used to analyze the data, the effect on the
ability to detect the sub-group was only minimal. When the size of group B was 20% of
the total population, changing either of these design factors resulted in an increase from
49% to 53% and 54%, respectively, of runs in which the sub-population was successfully
identified.

This study shows that, especially when the drug exhibits a high degree of interindividual
variability, in the range of 60%, a non-significant effect of a covariate may be a
consequence of inadequate power to detect an effect rather than a lack of effect
altogether. Only a maximum of approximately 60 - 70% of runs for a given design
successfully identified the sub-population in this study under these conditions. Thus,
caution needs to be taken when interpreting non-significant effects of covariates in
population pharmacokinetic studies.

The accuracy of estimates of the pharmacokinetic parameters of the model were used to
evaluate the different designs. When interindividual variability was low, accurate
estimates of CL in Group A, CL of group B and V d were obtained regardless of the size
of Group Band irrespective of the design used (Tables 4 and 5). Estimates of Vd were
stable across designs and different sizes of Group B. In all designs tested at least twothirds of the population were sampled during the period 0.08 to 1 hour after the dose. It is
the very early times after administration of a single dose that provides information about
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the parameter, Yd. Thus, it would appear that all of the designs included sufficient
information to accurately estimate V d. However, the designs differed in the amount of
information that was available to obtain estimates of CL. As previously mentioned, the
optimal time to obtain information about CL has been shown to be 1.4 -3 half-lives after
a dose. Both Designs 2 and 3 consisted of sampling windows that encompassed this
period and so they would be expected to perform better than Design 1. When the size of
the sub-population was 10 this was clearly evident, both bias and precision were
substantially worse with Design 1 as compared with Designs 2 and 3. In general, the
estimates of both CL of Group A and CL of Group B were worse for Design 1 as
compared to Designs 2 and 3. However, estimates were still within acceptable limits of
precision using Design 1.

When interindividual variability was high (60%), all 3 pharmacokinetic parameters were
estimated with less precision and greater bias than at the lower level of interindividual
variability (30%). Intuitively this makes sense that as the variability inherent in a
parameter increases it becomes harder to accurately estimate that parameter with the
same fixed population. Overall, the performance of Design 1 was poorest in terms of
estimating both CL of Group A and CL of Group B. This is likely to be due to the reason
given previously, the lack of informative data on these parameters. For Designs 1 and 3
there was marked improvement in the bias of the estimates of CL of Group B when the
size of that group was increased from 10 to 20. Very little change was observed when the
size of Group B was increased from 20 to 30. In contrast, Design 2 performed similarly in
terms of estimating the CL of Group B irrespective of the size of Group B. All
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individuals in Design 2 had a sample taken in the time range necessary to estimate CL
accurately, compared to only two-thirds of individuals in Design 3 and none in Design 1.
This may explain why Design 2 performed better than the other designs when the size of
Group B was 10. In general, using all designs, precision of CL estimates improved as the
size of Group B increased but estimates were acceptable at all levels. As seen with the
low level of interindividual variability, when interindividual variability was high,
estimates ofVd were stable and accurate in terms of both bias and precision across
designs and irrespective of the size of the sub-group.

It is accepted that for a fixed sample size, pharmacokinetic parameters are estimated more
accurately than the associated variability parameters (11 ,22,31). This observation was
confirmed at both levels of interindividual variability studied here. When interindividual
variability was low, Design 1 produced acceptable estimates of all variability parameters
in terms of bias yet all of the estimates were imprecise. In a previous simulation study,
Shein er and Beal found that an imprecise estimate of covd prohibited the detection of bias
in that parameter (3). Thus, the high level of imprecision observed in estimating all of the
variability parameters using Design 1 may have masked the ability for bias to be
detected . With Design 2 almost all of the parameters were biased regardless of the size of
the sub-group. However, precision of COcL was better with Design 2 than it was with
Design 1 although this was the only parameter using Design 2 to be acceptable in terms
of precision. This is probably a direct consequence of the more informative study design
with respect to CL. Design 3 performed the best overall in estimating the variability
parameters. The majority of parameters were acceptable in terms of bias, the exception
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being cr. Precision of estimates was relatively unaffected by the size of Group B and
estimates were precise or only marginally imprecise in most instances. Design 3 differed
from the two previous designs in that three sampling windows were used to obtain
samples even though the number of samples per individual remained at two. In so doing,
the whole of the concentration-time profile was covered from 0.08 hours to 24 hours after
the dose. Ensuring that samples were taken at random has been shown in the past to be a
robust design (1 , 12,32). The use ofrandom sampling can protect against misspecification
of the underlying structural model and situations where a single model is not adequate for
all individuals. Optimal sampling has been shown to be of benefit when samples are
sparse (33 ,34). However, a drawback to its use is that optimal sampling does not take
into consideration interindividual variability so an optimal time for one individual may be
sub-optimal for another especially if interindividual variability is high (18). The use of
sampling windows employed in Design 3 ensured that there was a randomness of the data
throughout the dosing interval including times that provide optimal information on the
parameters of the model. This may account for the superior performance of this design
compared to the other two designs. Using Design 3, when the size of Group B was 10 or
20, the variability estimates were virtually identical in terms of precision. When the size
of Group B was increased to 30, estimates of fficL and rovd improved but the estimate of cr
deteriorated. In a previous simulation study in which a 2 sample per individual design
was implemented, there was difficulty differentiating between interindividual and
intraindividual variability (15) . Inclusion of a third sample per individual was required to
effectively partition the two types of variability. At a low level of interindividual
variability, this phenomenon was apparent using Design 2 and Design 3. It was most
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obvious with Design 2 perhaps because of the large difference in time between the two
samples from each individual in this design (the first sample was taken between 0.08 and
1 hour and the second sample between 8 and 24 hours) . Some of the individuals in
Design 3 had samples taken closer together which may have aided in partitioning the
variability correctly with this design.

As seen with the pharmacokinetic parameters, estimation of the variability parameters
deteriorated when interindividual variability was increased to the higher level of 60%.
Design 2 performed worst overall at estimating the variability parameters at this level of
interindividual variability. All estimates were highly biased, especially estimates of a
which exceeded 300%. Estimates of CD cL and

CD v d

were for the most part precise but the

estimates of a were very imprecise. There was no trend for estimates to improve when
the size of Group B was increased. Both

CD cL

and

ro v d

were associated with negative

biases and a with positive biases. This is possibly a result of the difficulty in
differentiating between interindividual and intraindividual variability associated with the
2 sample design. None of the levels of Design 1 provided unbiased estimates of all of the
parameters. There was a trend for bias in

CD c L

and a to increase and bias in

ro v d

to

decrease as the size of Group B increased. This may be a consequence of the difficulty
associated with estimating these parameters from only two samples as already mentioned.
Design 3 provided unbiased estimates of ro v d irrespective of the size of group B and
unbiased estimates of CDcL only when the size of Group B was 30. In all cases, the
estimates of a were highly biased. There was no apparent trend in the precision of
parameter estimates using Design 3. When the size of the sub-group was 20, precision in
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COcL and rovd improved but at the expense of precision in cr. This problem in partitioning

variability was seen with all of the study designs although with Design 2 it was more
pronounced. With Designs 1 and 3, at least some of the individuals had samples that were
closer together in time which may have helped to partition the variability.

Design 3 in which the sub-population consisted of 20 individuals was chosen as a base
model to evaluate 3 additional modifications to the study design. First, the effect of
reducing the level of intraindividual variability was investigated (Design 4), second the
effect of increasing the size of the total study population was considered (Design 5) and
finally, the effect of using the FOCE algorithm in NONMEM instead of the FO method
was investigated (Design 6). Each additional factor was considered separately at the high
level of interindividual variability of 60%.

The level of intraindividual variability selected for this study (25%) represents a
moderately variable drug (16) . Previous simulation studies (3,11) have often used a more
modest level of 15%, a value these researchers feel is more commonly observed
clinically. When the effect of decreasing the intraindividual variability from 25% to 15%
was studied, the only parameter estimate that was markedly affected was cr. Both bias and
precision were worse when intraindividual variability was 15%. As previously
mentioned, when only two samples are taken per individual there are problems
distinguishing the two types of variability. The erroneous partitioning of interindividual
variability into intraindividual variability leads to a proportionally larger error in the
intraindividual variability when the starting value is low.
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Initially in this study, designs were investigated using a fixed number of samples per
individual in a fixed total population. Precision of parameter estimates is influenced by
the total size of the study population. Thus, increasing the size of the total population
from 100 individuals (Design 3) to 200 individuals (Design 5) should result in more
accurate parameter estimates. This is in fact what was observed (Table 9). The biggest
change occurred in the precision of CT which was much improved using Design 5 although
it was still not acceptable. The estimate of ro v d was slightly worse with Design 5 but still
within the acceptable limits. Thus, doubling the sample size did not lead to acceptable
estimates of all parameters although some improvement was observed. Using Design 5
the estimate of CDcL was unbiased and estimation of CL of Group B, ro v d and

CT

improved

in terms of bias when compared to Design 3. Increasing the total sample size further may
lead to further improvements in the parameter estimates.

The final factor to be evaluated was the effect of using the FOCE algorithm as
implemented in NONMEM. In early versions of the NONMEM program, only the FO
method was available. This method involves a linear approximation of the random effect
parameters in the model that may lead to bias in parameter estimates. In contrast, the
FOCE method does not use this linear approximation and so may be expected to produce
less biased parameter estimates. A problem in the past with the FOCE method was that it
is more complex than the FO method and so requires much more computer time to
perform an analysis especially with large data sets and/or complex structural models.
However, the improvement in the speed of computers means that this is not as great of an
issue today. In this study, there was a substantial difference between the two methods
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with respect to estimation of the variability parameters (Table 10). Using the FOCE
method, all parameters were precise and only cr was biased. However, with the FO
method, cr was more biased and imprecise and coc1 was biased. In general terms, all of the
variability parameters were better estimated when the FOCE method was used in
NONMEM as opposed to the FO method. This is in keeping with the observations of
Jonsson and colleagues who found that the FOCE method produced more accurate
estimates of some parameters (14).

CONCLUSIONS:
This study evaluated 3 sampling designs in various study populations. The designs were
evaluated in terms of their ability to provide accurate estimates of the parameters of the
model and to identify a sub-population with reduced clearance. These results show that
modification of various details of the design influenced the results obtained. In addition,
other factors such as the primary objectives of the study and the cost of analyzing
samples need to be taken into consideration when designing a population
pharmacokinetic study. Thus each population study should be considered on an
individual basis and the factors relevant to that situation can be assessed .

Under the conditions of this study, the following general conclusions on study design can
be drawn :
1. When interindividual variability was low (30%), a sub-group of 20 individuals was

adequate to detect a sub-group in which CL was reduced by 30% . No benefit was
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observed when the size of the sub-population was increased to 30 but there was
deterioration when the sub-population was reduced to 10.
2. When interindividual variability was high (60%), a sub-group of 30 was not enough
to consistently identify the sub-group. No design identified the sub-group more than
70% of the time. Thus, when interindividual variability was high, none of the 2
sample designs evaluated in this study could consistently identify a sub-group with a
30% reduced CL.
3. When interindividual variability was high, increasing the size of the sub-group
beyond 30% of the total population or increasing the number of samples per
individual may help to identify the sub-group. These effects were not investigated in
this study.
4. When interindividual variability was high, increasing the total size of the study
population from 100 individuals to 200 individuals resulted in marked improvement
in the ability to identify the sub-group.
5. Both pharmacokinetic parameters and variability parameters were more difficult to
estimate when interindividual variability was high.
6. All designs accurately estimated the pharmacokinetic parameters when
interindividual variability was 30%. At the 60% level, Vd estimates were stable and
estimates of CL were acceptable when study designs contained samples taken at later
times i.e. 1 to 3 half-lives after administration of the drug.
7. Of the 3 sampling designs investigated, one design consisted of 3 sampling windows
that covered a period of approximately 3 half-lives. This design performed the best
overall of the designs and when interindividual variability was low, most of the
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variability parameters could be estimated accurately using this design whereas the
other 2 designs performed badly at this level. When interindividual variability was
high, none of the designs tested were able to produce acceptable estimates of
variability parameters. Additionally, all designs suffered from the inability to
differentiate interindividual variability from intraindividual variability.
8. The difficulty in partitioning variability was more pronounced using a lower level of
intraindividual variability. When the true value for cr is lower, interindividual
variability that is wrongly partitioned as intraindividual variability will have a greater
effect upon the estimate of cr. This explains why the estimate of cr deteriorated at the
lower level of intraindividual variability.
9. Increasing the total size of the study population resulted in better detection of the subgroup and an increase in the accuracy of some parameter estimates.
10. At the high level of interindividual variability studied, the FOCE method resulted in
marked improvement of the variability estimates as compared to the FO method . Use
of the FOCE method did not affect the ability to detect the sub-population.

In summary, Design 3 performed best overall. This design consisted of 3 sampling
windows that ensured a random spread of the data throughout the dosing interval
including the optimal time periods to gain information on individual parameters.
However, at the high level of interindividual variability studied here ( 60% ), this design
still did not perform consistently.
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Table 1: Sampling Windows for Designs 1 to 3.

Design

Time of samples 1 and 2 (hrs)

1

0.08 - 1 and 7 - 8

2

0.08 - 1 and 8 - 24

0.08 - 1 and 1 - 8

or

3

0.08 - 1 and 8 - 24

or
1 - 8 and 8 - 24
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Table 2: Percent of NONMEM Runs in Which Group B was
Successfully identified when Interindividual Variability was 30%.

Design a

1
1
1

Number of Individuals

Percent Runs where Group B

in Group B

was Successfully Identified

10
20
30

59
73
84

10

2
2
2

20
30

67
94
97

3
3
3

10
20
30

74
93
93

a Details of Designs 1 to 3 are given in Table 1.
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Table 3: Number ofNONMEM Runs in Which Group B was

(

Successfully identified when lnterindividual Variability was 60%

Designa

Number of Individuals

Percent Runs where Group B

in Group B

was Successfully Identified

1

10

27

1

20

54

1

30

69

2

10

41

2

20

59

2

30

59

3

10

37

3

20

49

3

30

62

4

20

53

5

20

80

6

20

54

a Details of Designs 1 to 3 are given in Table 1. Designs 4 to 6 are the same as Design 3
except for the following modifications: Design 4 uses a level of intraindividual variability
of 15% (Design 3 uses 25%), the total population for Design 5 is 200 individuals (Design 3
is 100 individuals), and Design 6 was analyzed using the FOCE method in NONMEM
(Design 3 used the FO method).
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Table 4: Percent Bias of Parameter Estimates using all Three Designs when
Interindividual Variability in Clearance and Volume of Distribution were 30%.

Ratio of
Group A:
Grou_p_B
90:10

CL of
Group A

CL of
Group B

Vd

COcL

CO yd

3

-9

-7

5

2

10

80 :20

5

-1

-7

-5

10

3

l

70 :30

4

2

-7

10

7

-3

2b

90 : 10

-4

-6

-6

-27

-1 6

36

2

80:20

-4

-1

-5

-27

-16

31

2

70:30

-4

0

-6

-22

-11

31

3c

90:10

-l

-3

-5

-12

-3

11

3

80:20

-2

-3

-5

-12

-3

18

3

70:30

-2

0

-6

-13

-2

18

Design

l"

Abbreviations: CL =Clearance, Yd = Volume of Distribution, WCL represents interindividual variability of
CL, wvd represents interindividual variability of Yd, cr represents intraindividual variability.
• first sample taken between 0.08 and l hour and second sample taken between 7 and 8 hours.
b first sample taken between 0.08 and l hour and second sample taken between 8 and 24 hours.
c 2 samples taken from 2 of the 3 following sampling windows : 0.08 to l hour, l to 8 hours and 8 to 24
hours.
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Table 5: Percent Precision of Parameter Estimates using all Three Designs when
Interindividual Variability in Clearance and Volume of Distribution were 30%.

Design

Ratio of
Group A:
GrouJ!_B

CL of
Group A

CL of
Group B

Vd

ro cL

ffivd

er

l"

90:10

5

16

4

77

42

63

l

80:20

5

13

4

73

48

50

l

70:30

5

11

4

74

39

51

2b

90:10

3

11

3

28

39

57

2

80:20

4

8

4

27

48

61

2

70:30

4

7

4

32

44

60

3c

90:10

4

11

4

36

37

33

3

80:20

4

11

4

36

38

34

3

70:30

5

9

4

34

35

43

Abbreviations: CL =Clearance, Yd= Yolwne of Distribution, ro CL represents interindividual variability of
CL, ro vd represents interindividual variability of Yd, er represents intraindividual variability.
• first sample ta.ken between 0.08 and l hour and second sample taken between 7 and 8 hours.
b first sample taken between 0.08 and 1 hour and second sample taken between 8 and 24 hours.
c 2 samples taken from 2 of the 3 following sampling windows: 0.08 to l hour, 1 to 8 hours and 8 to 24
hours.
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Table 6: Percent Bias of Parameter Estimates using all Three Designs when
Interindividual Variability in Clearance and Volume of Distribution were 60%.

CL of
Group A

CL of
Grou11 B

Vd

o:>cL

o:>vd

l"

Ratio of
Group A:
Grou_J!_B
90 :10

13

-16

-12

-6

30

-23

l

80:20

13

2

-13

-9

10

31

70 :30

15

5

-13

-13

7

66

2b

90:10

-7

-9

-13

-58

-48

330

2

80 :20

-7

-9

-15

-63

-49

321

2

70 :30

-8

-7

-12

-59

-43

326

3c

90:10

6

-13

-12

-21

-1

79

3

80 :20

3

-5

-11

-25

-7

97

3

70 :30

4

-4

-1 2

-15

3

83

Design

Abbreviations: CL =Clearance, Yd= Volume of Distribution, WCL represents interindividual variability of
CL, wvd represents interindividual variability of Yd, cr represents intraindividual variability.
• first sample taken between 0.08 and l hour and second sample taken between 7 and 8 hours.
b first sample taken between 0.08 and 1 hour and second sample taken between 8 and 24 hours.
c 2 samples taken from 2 of the 3 following sampling windows: 0.08 to l hour, l to 8 hours and 8 to 24
hours.
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Table 7: Percent Precision of Parameter Estimates using all Three Designs when
Interindividual Variability in Clearance and Volume of Distribution were 60%.

CL of
Group A

CL of
Group B

Vd

CilcL

(i)yd

cr

i·

Ratio of
Group A:
Grouj>_B
90:10

9

25

7

27

43

109

1

80:20

9

17

6

47

48

165

1

70:30

8

18

5

55

39

162

2b

90:10

6

28

7

22

30

158

2

80:20

6

15

6

15

25

155

2

70:30

6

10

7

26

38

183

3c

90:10

9

21

9

38

45

99

3

80:20

7

14

7

28

26

102

3

70 :30

9

14

7

38

58

93

Design

(
Abbreviations: CL ==Clearance, Vd ==Volume of Distribution, roCL represents interindividual variability of
CL, rovd represents interindividual variability of Vd, cr represents intraindividual variability.
• first sample taken between 0.08 and 1 hour and second sample taken between 7 and 8 hours.
b first sample taken between 0.08 and 1 hour and second sample taken between 8 and 24 hours.
c 2 samples taken from 2 of the 3 following sampling windows: 0.08 to l hour, 1 to 8 hours and 8 to 24
hours.

(
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Table 8: Percent Bias and Precision of Parameter Estimates using Different Levels
of Intraindividual Variability.

Parameter

% Precision

% Bias

Design 3

Design 4

Design 3

Design 4

Group A CL

3

6

7

8

Vd

-11

-10

7

7

GroupB CL

-5

-2

14

14

COcL

-25

-21

28

25

covd

-7

-6

26

26

cr

97

163

102

208

(
Abbreviations: CL =Clearance, Yd= Volume of Distribution, co cL represents interindividual variability of
CL, covd represents interindividual variability of Yd, cr represents intraindividual variability.
Both Design 3 and Design 4 consist of 2 samples per individual taken from three sampling windows - see
Table 1.
Design 3: Intraindividual variability = 25%, interindividual variability = 60%.
Design 4: Intraindividual variability= 15%, interindividual variability= 60%.
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Table 9: Percent Bias and Precision of Parameter Estimates using Different Total
Numbers of Individuals.

Parameter

(

% Bias

% Precision

Design 3

Design 5

Design 3

Design 5

Group A CL

.....

.)

3

74

6

Vd

-11

-12

74

56

GroupB CL

-5

-1

14

136

COcL

-25

-12

28

266

covd

-7

-5

26

34

cr

97

86

102

72

Abbreviations: CL =Clearance, Vd = Volume of Distribution, ffi cL represents interindividuaJ variability of
CL, ffivd represents interindividuaJ variability of Vd, cr represents intraindividuaJ variability.
Both Design 3 and Design 5 consist of 2 samples per individual taken from three sampling windows - see
Table l.
Design 3: Total number of individuals= 100, interindividual variability = 60%, intraindividuaJ variability =
25%.
Design 5: Total number of individuals= 200, interindividual variability = 60%, intraindividuaJ variability =
25%.
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Table 10: Percent Bias and Precision of Parameter Estimates obtained when the FO
Method was compared to the FOCE Method.

% Precision

% Bias

Parameter
Design 3

Design 6

Design 3

Design 6

Group ACL

3

9

7

11

Vd

-11

-6

7

7

Group B CL

-5

-8

14

13

<DcL

-25

10

28

24

<Dvd

-7

-2

26

21

CJ

97

-45

102

25

Abbreviations: CL =Clearance, Yd= Volume of Distribution, coCL represents interindividual variability of
CL, covd represents interindividual variability of Yd, cr represents intraindividual variability.
Both Design 3 and Design 6 consist of 2 samples per individual taken from three sampling windows - see
Table l.
Design 3: FO method used, interindividual variability = 60%, intraindividual variability = 25%.
Design 6: FOCE method used, interindividual variability= 60%, intraindividual variability= 25%.
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Figures la - b: Percent Runs in which Group B was
Successfully Identified

Figure la: Interindividual Variability set at 30%
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Figure lb: Interindividual Variability set at 60%
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Design I: I sample. taken between 0.08 and 1 hour, and I taken between 7 and 8 hours
Design 2: 1 sample taken between 0.08 and 1 hour, and I taken between 8 and 24 hours
Design 3: 2 samples taken from 2 of 3 sampling windows: 0.08 to I hour, I to 8 hours
and 8 to 24 hours
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Figures 2a - c: Percent Bias in Pharmacokinetic Parameter Estimates
when Interindividual Variability is Set at 30%.
Figure 2a: Design 1
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and 8 to 24 hours
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Figures 3a - c: Percent Precision in Pharmacokinetic Parameter Estimates
when Interindividual Variability is Set at 30%.
Figure 3a: Design 1
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and 8 to 24 hours
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Figures 4a - c: Percent Bias in Pharmacokinetic Parameter Estimates
when Interindividual Variability is Set at 60%.

Figure 4a: Design 1
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Figure 4b: Design 2
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Figures Sa - c: Percent Precision in Pharmacokinetic Parameter Estimates
when Interindividual Variability is Set at 60%.
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Figures 6a - c: Percent Bias in Variability Parameter Estimates
when Interindividual Variability is Set at 30%.
Figure 6a: Design 1
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Figures 7a - c:

Percent Precision in Variability Parameter Estimates
when Interindividual Variability is Set at 30%.
Figure 7a: Design 1
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Figures Sa - c: Percent Bias in Variability Parameter Estimates
when Interindividual Variability is Set at 60%.
Figure Sa: Design 1
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Figures 9a - c: Percent Precision in Variability Parameter Estimates
when Interindividual Variability is Set at 60%.
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FigureslOa - b: Percent Bias and Precision in Parameter Estimates
comparing Design 3 to Design 4.
Figure lOa: Percent Bias in Parameter Estimates
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Figure lOb: Percent Precision in Parameter Estimates
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Figureslla - b: Percent Bias and Precision in Parameter Estimates
comparing Design 3 to Design 5.

Figure lla: Percent Bias in Parameter Estimates
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Figure llb: Percent Precision in Parameter Estimates
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Figuresl2a - b: Percent Bias and Precision in Parameter Estimates
comparing Design 3 to Design 5.

Figure 12a : Percent Bias in Parameter Estimates
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Figure 12b : Percent Precision in Parameter Estimates
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Design 6: FOCE method in NONl'vtEM used to analyze the data.
Design 3 and 4 each consist of 2 samples per individual taken from 2 of 3 sampling windows:
0.08 to I hour, 1 to 8 hours and 8 to 24 hours
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SUMMARY OF CONCLUSIONS

The population approach to pharmacokinetic analysis is a relatively new approach that
has gained acceptance as a tool to aid in the drug development process. This is illustrated
by the number of articles on the subject that have been published recently, both reviewing
and applying the methodology, and the publication by the Federal Drug Administration
(FDA) of a document in February 1999 providing guidance to the pharmaceutical
industry on the conduct, design and analysis of these studies.

A major advantage of the population approach is the ability to apply the methodology in
situations when only sparse data per individual is available. By doing so, large,
heterogeneous populations can be studied to obtain estimates of the variability of the
pharmacokinetics of the drug in a population more representative of the true population
to be treated. Additionally, the effects of patient covariates, such as body weight and
gender, can be evaluated for an influence on the pharmacokinetic parameters and the
variability of the drug. If applicable, decisions to modify the dose in specific subpopulations can then be taken based on this knowledge.

The pharmacokinetic parameters of the protease inhibitor, nelfinavir were determined
using sparse data obtained from patients enrolled in a phase III clinical study and the
effects of patient covariates on the pharmacokinetic parameters were investigated. The
data was such that the majority of patients in the study had blood samples taken on two
study visits for analysis of nelfinavir concentrations. Two samples were taken on each
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occasion in accordance with a study protocol at two hours post-dose and immediately
pre-dose.

The results showed first, that clearance was estimated accurately and the estimate
obtained was in agreement with the estimates from previously conducted traditional
studies. However, problems were encountered in estimating the other structural model
parameters, volume of distribution and the absorption rate constant in addition to their
variability. This was likely to be a consequence of the study design. Information early in
the dosing interval, the period that contains information on volume of distribution and the
absorption rate constant, was insufficient. There was only one early sample per dosing
interval for each patient and there was very little variability in the timing of these
samples, most were around 2 hours post dose. In contrast, there was good spread of the
data at later time points allowing accurate estimation of clearance. Optimal sampling
times were used in this study to obtain information on the pharmacokinetics of nelfinavir.
It has previously been shown that there are pitfalls to the use of optimal sampling times
e.g. ifthere is model misspecification or high interindividual variability which resulted in
sub-optimal times for some patients. Random sampling has been advocated by many
investigators to protect against this happening. The randomness of the later time points
allowed clearance to be accurately estimated.

In an attempt to assess the impact of poor estimation of volume of distribution and the
absorption rate constant on the estimation of clearance, these parameters were fixed to
values obtained from analysis of more extensive data. When the data was re-analyzed
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using this model, the estimates obtained for clearance and its variability were similar to
the previous estimates obtained when volume of distribution and the absorption rate
constant were not fixed . Thus the inability to determine volume of distribution and the
absorption rate constant did not affect the ability to estimate clearance.

Due to the difficulties in estimating volume of distribution, the effects of various patient
covariates were only evaluated on clearance. Concomitant use of the azole antifungal,
fluconazole was the only covariate found to significantly effect clearance. It resulted in a
reduction in clearance of nelfinavir of approximately 30%. Concomitant use ofrifabutin
had previously been shown to affect clearance but it was not significant in this analysis.
This was probably due to lack of power to detect the effect rather than a lack of effect
altogether as only 5 of 174 patients were taking this concomitant drug.

Analysis of this real data set highlighted the fact that a well designed study is essential if
accurate pharmacokinetic parameters are to be obtained and the effects of covariates are
to be identified when the population approach is applied to sparse data. Simulation
studies can be effectively used to investigate various design issues prior to conducting the
study. Thus, a study using simulated data was conducted to evaluate different study
designs on the ability to accurately determine parameter estimates. Additionally, the
effect of different sizes of a sub-population, in which clearance is reduced by 30%, was
evaluated on the ability to detect that sub-population.
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The study evaluated 3 different study designs each comprising 2 samples per individual
in 100 individuals. Individuals were sampled from 2 groups, Group A in which
individuals had a ' normal ' value of clearance and Group Bin which individuals had a
30% reduced value of clearance. The one-compartment model with intravenous input was
used and two levels of interindividual variability were investigated, a low level of30%
and a high level of 60%. lntraindividual variability was fixed at 25%.

The ability to detect the sub-population with reduced clearance was better when
interindividual variability was low. When Group B consisted of 20 individuals this subpopulation could be consistently identified with the designs that included sampling times
1 to 3 half-lives after the dose was administered. At the high level of interindividual

variability, none of the designs investigated were consistently able to identify the sub(

population even when that population consisted of 30 individuals. Increasing the total
number of subjects aided in identifying the sub-population when interindividual
variability was high .

Both pharmacokinetic parameters and variability parameters were more difficult to
estimate when interindividual variability was high. Pharmacokinetic parameters were
accurately estimated when interindividual variability was 30% . The designs with the later
sampling times were also able to estimate the pharmacokinetic parameters accurately
when interindividual variability was 60%.
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One of the designs investigated performed better than the other designs . It consisted of 3
sampling windows that covered a period of approximately 3 half-lives. When
interindividual variability was low, most of the variability parameters could be estimated
accurately using this design whereas the other 2 designs performed badly even at this
level. None of the designs tested were able to produce acceptable estimates of variability
parameters at the high level of variability. Problems were encountered in estimating the
variability parameters using all of the designs due to the inability to differentiate
interindividual variability from intraindividual variability.

Various other design factors were altered to see if accurate variability parameter
estimates could be obtained. Although increasing the size of the total study population or
using the FOCE algorithm in NONMEM resulted in improvements in parameter
estimates, none of the designs provided unbiased and precise estimates of all of the
variability parameters.

A well designed 2 sample per individual study produced accurate parameter estimates
and identified a sub-population with a 30% reduction in clearance when interindividual
variability was low (30%). However, when interindividual variability was high (60%),
this design had problems identifying the sub-population and estimating some of the
variability parameters of the model.
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APPENDIX A
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The following tables and figures provide additional data on the modeling process that
was employed in Manuscript II.

Two data sets were used tn the population analysis of nelfinavir detailed in Manuscript II
of this dissertation. To di ferentiate between the two data sets, the original data will be
referred to as the populat on data and the data used to obtain estimates of V d/F and ka
will be referred to as the 'Taditional data. During analysis of the population data set,
difficulty was encountered in estimating volume of distribution (Vd/F) and the absorption
rate constant (ka). To assess the impact of fixing these two parameters to known values
on the ability to estimate CL/F and to assess the effect of covariates on this parameter, the
analysis was repeated using fixed values for these two parameters obtained from analysis
of data from a traditional study. Prior estimates of ka had not been reported in the
literature hence the reason this data was obtained. Initially a decision had to be made on
whether to combine the two data sets. The results of analyses using both data sets alone
and the combination of the two are shown in table 1. Addition of a lag time to the one
compartment model did not provide a better fit to either the population or the traditional
data alone whereas a mode l incorporating a lag time did provide a better fit to the data
when the two data sets w ere combined. There was no apparent reason as to why this was
the case. The estimates of CL/F were similar irrespective of the model used to fit to the
data or the data set used . The similarity of the estimates of CL/F, the lack of need for a
lag time parameter when the data sets were analyzed separately and the lack of covariate
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information contained in the traditional data resulted in the population data set alone
being used for further analyses. The traditional data set was used solely to provide
estimates of Vd/F and ka to be used as fixed values for further analyses of the population
data only. These values were 229 Land 0.845 h- 1 for Vd/F and ka, respectively .

Table 1: Parameter Estimates of the Basic Models of the Different Data Sets.
Theta 1
_{_CL_}_

Theta 2

Theta 3

1Y_cll

-~a)

467.7

40.7

733

1.21

population data only - lag time
in model

466.96

41.l

743

1.53

3

traditional data only - no lag
time in model

-106.6

39. l

229

0.845

4

traditional data only- lag time
in model

-105.6

37.8

286

1.02

5

traditional and population data
- no lag time in model

504

39 .9

627

0.953

6

traditional and population data
- no lag time in model, where
VIF constrained to be low

Would not
converge

7

traditional and po pulation data
- lag time in model

494.4

40.2

631

l.51

Model

Descri11tion of Model and
Data

MOF

l

population data only - no lag
time in model

2

Abbreviations: MOF = minim un value of the objective function, CL/F - clearance, Vd/F - volume of
distribution , ka - absorption rnte constant
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Table 2: Basic Model Parameter Estimates using Four Different Models

Model Criteria

CL/F (L/hr)

Vd/F (L)

ka (h- 1)

Eta !(Estimate of
variability in CL)

All parameters estimated

40.7

733

1.21

0.13

Vd/F fixed to 229 L

38.5

229

0.155

0.129

ka fixed to 0.845 h-1

40.2

660

0.845

0.127

Vd/F fixed to 229 L and

39.4

229

0.845

0.152

ka fixed to 0.845 lf1

Abbreviations: CL/F = cleararce, Vd/F =volume of distribution, ka =absorption rate constant.

Initially, four different models were fitted to the population data set and the basic models
were evaluated (Table 2). Three of the models used a fixed estimate for Vd/F, ka or both
parameters. The parameter(s) were fixed to the estimates obtained from analysis of the
traditional data as mentioned previously. These results showed that estimates of CL/F
were similar irrespective of the model used. Only two of these models were used in the
full analysis of the population data in Manuscript II. These were Model 1 (all parameters
are estimated) and Model 2 (Vd/F fixed to 229 Land ka fixed to 0.845 h- 1) .

(
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Table 3: Results of Covariates that were found to be Statistically Significant in

(

Clearance using Four Different Models 3 •

Model Criteria

Cd4

Mac

Rif

Flu

All parameters estimated

0.81

0.76

1.55

0.74

V d/F fixed to 229 L

0.81

0.75

1.53

0.74

ka fixed to 0.845 h- 1

0.81

0.76

1.53

0.74

Vd/F fixed to 229 L and

0.83

0.77

1.37b

0.73

ka fixed to 0.845 h- 1

Abbreviations: cd4 - CD4 count less than 100 cells per µl, mac= concomitant therapy with a macrolide
antibiotic, rif= concomitant therapy with rifabutin, flu= concomitant therapy with fluconazole, Vd/F =
volume of distribution, ka

= absorption rate constant, NS = not statistically significant.

• This table lists the proportionality constants that clearance (CL/F) is multiplied by when patients in the
study possessed the characteri stic of interest e.g. CL/F = CL/F * 0.812 for patients with a CD4 count less
than 100 cells per µl using the model in which all parameters were estimated i.e. patients with a low CD4
count have a typical value of clearance that is 81 % of the typical value of CL/F for patients who do not
have a low CD4 count.
b

When the model in which both ka and Yd were fixed was used, the effect of rifabutin on CL/F was not

significant although the direction and magnitude of the effect were similar to the estimates obtained using
the other models.
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Table 4: Results of Covariates tested for an Effect on Clearance using Model 1 and
Model 2 (FO Method).

Model One
Effect on
Significance
CUF"
0.11
NS
-0.01
NS
0.97
NS
0.89
NS
0.98
NS
1.15
NS
1.23
NS
l.28
NS
0.95
NS
0.96
NS
0.81
Significant
1.08
NS

Model Two
Effect on
Significance
CUF"
0.11
NS
-0.05
NS
1.03
NS
0.88
NS
1.08
NS
1.03
NS
1.19
NS
1.2 l
NS
1.21
NS
1.29
Borderline
0.83
Significant
1.05
Not
Significant
1.1
NS
0.87
Borderline

Covariate tested

6inMOF

Wt
Age
Gender
Race = Caucasian
Race= Black
Race= Asian
Race = Hispanic
Race = Latin American
Race =Native American
Dose (500rng or 750rng tid)
CD4 < 100 cells per µI
CD4 > 100 and < 300 cells
per µl
CD4 > 300 cells per µl
RNA> 100,000copies/ml

0.24
0.003
0.17
2.02
0.03
0.55
2.19
l .43
0.05
0.39
10.01
1.76
2.05
5.28

1.08
0.88

NS
Borderline

2.37
5.15

RNA> 50,000 and<
100,000 copies /ml
RNA< 50,000 copies /ml

0.25

1.03

NS

0.06

l.02

NS

.u

1.13

Borderline

4.84

1.15

Borderline

0

I

NS

0.04

0.98

NS

10.78

0.76

Significant

10.13

0.77

Significant

6.04

1.55

Significant

3.01

l.37

NS

17.23

0.74

Significant

18.53

0.73

Significant

0.002
2.65
1.66
0.08
0.77
1.71

1
0.90
8.79
0.98
0.95
1.09

NS
NS
NS
NS
NS
NS

0.29
2.29
1.11
0.21
0.20
118

1.03
0.91
7.54
0.97
0.97
1.08

NS
NS
NS
NS
NS
NS

Concomitant therapy with
quinolone antibiotic.
Concomitant therapy with
macrolide antibiotic.
Concomitant therapy with
rifabutin.
Concomitant therapy with
fluconazole .
History of Ii ver disease
RaisedLFTs
Metabolizing status
Poor rnetabolizer
Intermediate metabolizer
Extensive rnetabolizer

6inMOF
1.57
0.11
0.14
2.67
0.50
0.03
1.11
0.81
0.52
5.77
7.00
0.66

• Effect on Clearance (CL/F): if tl1e patient possesses the characteristic of column 1 then the typical value of CL/F
should be multiplied by the constant in this column e. g. using model 1, a patient taking concomitant fluconazole has a
significantly reduced clearance o! 74% (typical value*0.74).
A covariate was considered statis1ically significant ifthe 6 in the MOF when comparing the basic model to the full
model was 3.8 or greater and the ')5% confidence interval for the effect did not contain the null value (the null value
was either 0 or 1 depending on th1! covariate to be tested). A covariate was considered of borderline significance if the
6 in the MOF was 3.8 or greater ~ nd tl1e 95% confidence interval for the effect contained the null value. If the 6 in tl1e
MOF was less than 3.8 then tl1e c1wariate was considered to be not significant.
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Table 5: Results of Covariates tested for an Effect on Clearance using Model 1 and
Model 2 (FOCE Method).
Model One
Effect on Significance
CL/F"

Model Two
Effect on Significance
CL/F"

Covariate tested

6in
MOF

Wt
Age
Gender
Race = Caucasian
Race =Black
Race= Asian
Race = Hispanic
Race = Latin American
Race= Native American
Dose (500mg or 750mg
tid)
CD4 < 100 cells per µl
CD4>100 and< 300
cells per µl
CD4 > 300 cells per µ l
RNA> 100,000copies/ml

0 92
0.001
0 08
0 64
0 14
0.17
l 29
l 12
0 23
l 39

0.09
-0 .01
0.97
0.93
0.95
1.09
1.2
1.3
0.88
0.9

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

1.14
0.32
0.08
1.66
0.60
-2.29
0.31
-1.41
-2 .12
-3.20

0.11
-0 .09
1.03
0.89
11
l
1.1
1.27
1.17
1.1

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

5.16
0 20

0.84
1.03

Borderline
NS

0.57
-2.28

0.86
1.01

NS
NS

I 97
2 94

1.09
0.89

NS
NS

-0 .56
0.54

l.l
0.88

NS
NS

RNA> 50,000 and<
100,000 copies /ml
RNA< 50,000 copies /ml

0 47

0.95

NS

0.04

0.99

NS

5.99

1.18

Borderline

1.06

1.15

NS

0 07

1.03

NS

-2.17

1.05

NS

4.66

0.80

Borderline

1.48

0.81

NS

3 56

1.44

NS

1.54

1.31

NS

13.02

0.74

Signifi cant

12.0

0.70

Significa nt

0 11
1 15
0 21
0 05
0 81
0 61

1.02
0.93
3.74
1.01
0.94
1.06

NS
NS
NS
NS
NS
NS

0.03
-1 .20
-2 .23
0.48
-1.48
-2.26

1.01
0.92
-2.31
1.05
0.94
1.0 I

NS
NS
NS
NS
NS
NS

Concomitant therapy
with a quinolone
antibiotic.
Concomitant therapy
with a macrolide
antibiotic.
Concomitant therapy
with rifabutin.
Concomitant therapy
with fluconazo le.
History of liver disease
RaisedLFTs
Metabolizing status
Poor metabolizer
futermediate metabolizer
Extensive metabolizer

6. in

MOF

•Effect on clearance (CL/F): if th<! patient possesses the characteristic of colunm l then the typical va lue of CL/F
should be multiplied by the constnnt in this column e.g. using model I, a patient taking concomitant fluconazole has a
significantly reduced clearance or74% (typical value*0.74).
A covariate was considered signilicant if the ti in the MOF when the full model was compared to the reduced model
was 3.84 or greater and the 95% confidence interval for the effect did not contain the null value (the null value was
either 0 or 1 depending on the co,·ariate to be tested). A covariate was considered of borderline significance if the 6 in
the MOF was 3.8 or greater and the 95% confidence interval for the effect contained the null value. If the ti in the MOF
was less than 3.8 then the covariate was considered to be not significant.
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Figure 1: Concentration versus Time for Patient who received a dose of SOOmg three times a
day.
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Figure 2: Concentration versus Time for Patient who received a dose of 750mg three times a
day.
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Figure 3: NONMEM Control File for the Final Model (Model 1 and FO Method)

$PROBLEM nelfinavir data, agouron ag5 llpk (Feb 99)
$INPUT
ID TIME Af.1T SS II DV TAD MET METC MAC RIF AZO FLU L VHX
$INPUT
LFT CD4
$DATA
NFVF LRECL=80
$SUBROUTINES ADV AN2 TRANS2 SS2

(

$PK TVCL=THETA( L)*(l-THETA(4)*FLU)
TVV=THET A(2)
TVKA=THETA(3)
CL=TVCL *EXP(ETA(l ))
V=TVV
KA=TVKA*EXP(ETA(2))
S2=V
$THETA (10,30,80) (150,600, 1000) (0.05, 1,3)
(0,0.3,1)
$OMEGA (.25) (.25)
$ERROR Y=F*(l +ERR( l )) + ERR(2)
$SIGMA 0.10 0.10
$ESTIMATION MAXEVAL=5000 PRINT=5 POSTHOC
$COVARIANCE
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Figure 4: NONMEM Control File for the Final Model (Model 1 and FOCE Method)

$PROBLEM nelfinavir data, agouron ag511 pk (Feb 99)
$INPUT
ID TIME Al\1T SS II DV TAD MET METC MAC RIF AZO FLU L VHX
$INPUT
LFT CD4
$DAT A
NFVF LRECL=80
$SUBROUTINES ADVAN2 TRANS2 SS2

(

$PK TVCL=THETA(1)*(1-THETA(4)*FLU)
TVV=THET A(2)
TVKA=THETA(3)
CL=TVCL *EXP(ETA(l ))
V=TVV*EXP(ETA(2))
KA=TVKA *EXP(ETA(3))
S2=V
$THETA (10,30,80) (1 50,600, 1000) (0.1,1,3)
(0,0.3, 1)
$OMEGA (.25) (.25 ) (.:'. 5)
$ERROR Y=F*(l +ERR( L)) + ERR(2)
$SIGMA0 .10 0.10
$ESTIMATION MAXEV AL=5000 PRINT=5 POSTHOC METHOD= l
$COVARIANCE
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Figure 5: NONMEM Control File for the Final Model (Model 2 and FO Method)

$PROBLEM nelfinavir data, agouron ag51 lpk (Feb 99)
$INPUT
ID TIME M1T SS II DV TAD MET METC MAC RIF AZO FLU L VHX
$INPUT
LFT CD4
$DATA
NFVF LRECL=80
$SUBROUTINES ADVAN2 TRANS2 SS2

(

$PK TVCL=THETA(l)*(l-THETA(4)*FLU)
TVV=THET A(2)
TVKA=THETA(3)
CL=TVCL *EXP(ETA(l ))
V=TVV*EXP(ETA(2))
KA=TVKA
S2=V
$THETA (10,30,80) (229 FIXED) (0.845 FIXED)
(0,0.3, 1)
$OMEGA (.25) (.25)
$ERROR Y=F*(l +ERR(l)) + ERR(2)
$SIGMA 0.10 0.10
$ESTIMATION MAXEV.J\L=5000 PRINT=5 POSTHOC
$COVARIANCE
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Figure 6: NONMEM Control File for the Final Model (Model 2 and FOCE Method)

$PROBLEM nelfinavir data, agouron ag51 lpk (Feb 99)
$INPUT
ID TIME Af.1T SS II DV TAD MET METC MAC RIF AZO FLU L VHX
$INPUT
LFT CD4
$DATA
NFVF LRECL=80
$SUBROUTINES ADV 1\N2 TRANS2 SS2

(

$PK TVCL=THETA( 1)*( l-THETA(4)*FLU)
TVV=THET A(2)
TVKA=THETA(3)
CL=TVCL *EXP(ETA(l))
V=TVV*EXP(ET A(2))
KA=TVKA
S2=V
$THETA (10,30,80) (229 FIXED) (0 .845 FIXED)
(0,0.3, 1)
$OMEGA (.25) (.25)
$ERROR Y=F*(l+ERR(l)) + ERR(2)
$SIGMA 0.10 0.10
$ESTIMATION MAXEY AL=SOOO PRINT=S METHOD=l
$COVARIANCE
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